Track market-moving stories before they get noisy

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) as monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and are not candidates for PD-1 or PD-L1 inhibitor therapy. Trodelvy is the first antibody-drug conjugate (ADC) to be approved in first-line metastatic TNBC in the European Union’s 27 member states, as well as Norway, Iceland and Liechtenstein.

“This approval brings a profound sense of hope to a community that has long been waiting for progress,” said Dr. Javier Cortes, Head of the International Breast Cancer Center, Madrid and Barcelona, Spain. “For women diagnosed with metastatic TNBC, particularly those who are younger, every second counts, and having an effective treatment option that can delay the progression of their disease is invaluable. This is the kind of meaningful advance our community needs.”

For many living with metastatic TNBC, the most aggressive form of breast cancer, first-line therapy may be their only line of treatment, creating an urgent need for effective treatment options to be used as early as possible.

“This approval represents a significant step forward in how we treat people with first-line metastatic TNBC in Europe,” said Mika Kakefuda Derynck, MD, Senior Vice President, Clinical Development, Oncology at Gilead Sciences. “We have long recognized the challenges that patients and clinicians face with this aggressive cancer, and we believe this approval will provide a much-needed new option for people with metastatic TNBC.”

The EC’s marketing authorization is based on data from the Phase 3 ASCENT-03 study which demonstrated a highly statistically significant and clinically meaningful progression-free survival for Trodelvy compared to standard of care chemotherapy as a first-line treatment. In ASCENT-03, Trodelvy demonstrated a 38% reduced risk of disease progression or death in patients who are not candidates for PD-1/PD-L1 inhibitors. The ASCENT-03 study utilized a patient-centered crossover design, which allowed patients in the chemotherapy arm to receive Trodelvy after their disease progressed. The EC’s approval, based on the strength of the PFS data, confirms the study's objective to demonstrate using Trodelvy earlier provides a clinical benefit over chemotherapy for metastatic TNBC patients.

Continued Global Regulatory Filings for Trodelvy in First-Line Metastatic TNBC

Gilead has submitted a supplemental filing to the European Medicines Agency for Trodelvy in combination with Keytruda® (pembrolizumab) for patients with PD-L1 positive unresectable locally advanced or metastatic TNBC, based on data from the Phase 3 ASCENT-04 study. This application is currently under review. If approved, Trodelvy has the potential to be a backbone treatment in 1L metastatic TNBC, across PD-L1 status in Europe. In the U.S., Gilead has also submitted supplemental filings to the Food and Drug Administration (FDA) for Trodelvy for the first-line treatment of adult patients with unresectable locally advanced or metastatic TNBC as a single agent for patients who are not candidates for PD-(L)1 inhibitor-based therapy, or in combination with Keytruda or Keytruda Qlex in patients whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-authorized test.

KEYTRUDA® and KEYTRUDA QLEX™ are trademarks of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

About Triple-Negative Breast Cancer In Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitors

TNBC is the most aggressive type of breast cancer and has historically been difficult to treat, accounting for approximately 15% of all breast cancers. TNBC disproportionally impacts younger, premenopausal, and Black and Hispanic women. TNBC cells do not have estrogen and progesterone receptors and have limited HER2 expression. Due to the nature of TNBC, treatment options are extremely limited compared with other breast cancer types. TNBC has a higher chance of recurrence and metastases than other breast cancer types. The average time to metastatic recurrence for TNBC is approximately 2.6 years compared with 5 years for other breast cancers, and the relative five-year survival rate is much lower. Among women with metastatic TNBC, the five-year survival rate is 12%, compared with 28% for those with other types of mBC.

About Trodelvy

Trodelvy (sacituzumab govitecan-hziy) is a Trop-2-directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and lung cancers. Trodelvy is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload. This unique combination delivers potent activity to both Trop-2 expressing cells and the tumor microenvironment through a bystander effect.

Outside of Europe, Gilead has submitted supplemental applications to the U.S. Food and Drug Administration (FDA) for approval of Trodelvy based on the ASCENT-03 and ASCENT-04 studies.

Healthcare professionals have substantial clinical experience with Trodelvy, with more than 75,000 breast cancer patients treated since 2020. In addition to its first-line indication approval, Trodelvy is currently approved in more than 60 countries for patients with second-line or later mTNBC and in over 50 countries for certain patients with pre-treated HR+/HER2- metastatic breast cancer. It is the only ADC with four positive Phase 3 trials in HER2-negative metastatic breast cancer and the only Trop-2-directed ADC to demonstrate a meaningful overall survival benefit in two distinct types of metastatic breast cancer.

Trodelvy is currently being evaluated in multiple ongoing Phase 3 trials across different tumor types, including in small cell lung cancer and gynecologic cancers, where previous proof-of-concept studies have demonstrated clinical activity.

U.S. Indications for Trodelvy

TRODELVY® (sacituzumab govitecan-hziy) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with:

Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. U.S. Important safety information FOR TRODELVY
BOXED WARNING: NEUTROPENIA AND DIARRHEA

TRODELVY can cause severe, life-threatening, or fatal neutropenia. Withhold TRODELVY for absolute neutrophil count below 1500/mm3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Primary prophylaxis with G-CSF is recommended for all patients at increased risk of febrile neutropenia. Initiate anti-infective treatment in patients with febrile neutropenia without delay. TRODELVY can cause severe diarrhea. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤ Grade 1 and reduce subsequent doses. CONTRAINDICATIONS

Severe hypersensitivity reaction to TRODELVY. WARNINGS AND PRECAUTIONS

Neutropenia: Severe, life-threatening, or fatal neutropenia can occur as early as the first cycle of treatment and may require dose modification. Neutropenia occurred in 64% of patients treated with TRODELVY. Grade 3-4 neutropenia occurred in 49% of patients. Febrile neutropenia occurred in 6%. Neutropenic colitis occurred in 1.4%. Primary prophylaxis with G-CSF is recommended starting in the first cycle of treatment in all patients at increased risk of febrile neutropenia, including older patients, patients with previous neutropenia, poor performance status, organ dysfunction, or multiple comorbidities. Monitor absolute neutrophil count (ANC) during treatment. Withhold TRODELVY for ANC below 1500/mm3 on Day 1 of any cycle or below 1000/mm3 on Day 8 of any cycle. Withhold TRODELVY for neutropenic fever. Treat neutropenia with G-CSF and administer prophylaxis in subsequent cycles as clinically indicated or indicated in Table 2 of USPI.

Diarrhea: Diarrhea occurred in 64% of all patients treated with TRODELVY. Grade 3-4 diarrhea occurred in 11% of patients. One patient had intestinal perforation following diarrhea. Diarrhea that led to dehydration and subsequent acute kidney injury occurred in 0.7% of all patients. Withhold TRODELVY for Grade 3-4 diarrhea and resume when resolved to ≤ Grade 1. At onset, evaluate for infectious causes and if negative, promptly initiate loperamide, 4 mg initially followed by 2 mg with every episode of diarrhea for a maximum of 16 mg daily. Discontinue loperamide 12 hours after diarrhea resolves. Additional supportive measures (e.g., fluid and electrolyte substitution) may also be employed as clinically indicated. Patients who exhibit an excessive cholinergic response to treatment can receive appropriate premedication (e.g., atropine) for subsequent treatments.

Hypersensitivity and Infusion-Related Reactions: TRODELVY can cause serious hypersensitivity reactions including life-threatening anaphylactic reactions. Severe signs and symptoms included cardiac arrest, hypotension, wheezing, angioedema, swelling, pneumonitis, and skin reactions. Hypersensitivity reactions within 24 hours of dosing occurred in 35% of patients. Grade 3-4 hypersensitivity occurred in 2% of patients. The incidence of hypersensitivity reactions leading to permanent discontinuation of TRODELVY was 0.2%. The incidence of anaphylactic reactions was 0.2%. Pre-infusion medication is recommended. Have medications and emergency equipment to treat such reactions available for immediate use. Observe patients closely for hypersensitivity and infusion-related reactions during each infusion and for at least 30 minutes after completion of each infusion. Permanently discontinue TRODELVY for Grade 4 infusion-related reactions.

Nausea and Vomiting: TRODELVY is emetogenic and can cause severe nausea and vomiting. Nausea occurred in 64% of all patients treated with TRODELVY and Grade 3-4 nausea occurred in 3% of these patients. Vomiting occurred in 35% of patients and Grade 3-4 vomiting occurred in 2% of these patients. Premedicate with a two or three drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK1 receptor antagonist as well as other drugs as indicated) for prevention of chemotherapy-induced nausea and vomiting (CINV). Withhold TRODELVY doses for Grade 3 nausea or Grade 3-4 vomiting and resume with additional supportive measures when resolved to Grade ≤ 1. Additional antiemetics and other supportive measures may also be employed as clinically indicated. All patients should be given take-home medications with clear instructions for prevention and treatment of nausea and vomiting.

Increased Risk of Adverse Reactions in Patients with Reduced UGT1A1 Activity: Patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia and may be at increased risk for other adverse reactions with TRODELVY. The incidence of Grade 3-4 neutropenia was 58% in patients homozygous for the UGT1A1*28, 49% in patients heterozygous for the UGT1A1*28 allele, and 43% in patients homozygous for the wild-type allele. The incidence of Grade 3-4 anemia was 21% in patients homozygous for the UGT1A1*28 allele, 10% in patients heterozygous for the UGT1A1*28 allele, and 9% in patients homozygous for the wild-type allele. Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue TRODELVY based on clinical assessment of the onset, duration and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually severe adverse reactions, which may indicate reduced UGT1A1 function.

Embryo-Fetal Toxicity: Based on its mechanism of action, TRODELVY can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TRODELVY and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TRODELVY and for 3 months after the last dose.

ADVERSE REACTIONS

In the pooled safety population, the most common (≥ 25%) adverse reactions including laboratory abnormalities were decreased leukocyte count (84%), decreased neutrophil count (75%), decreased hemoglobin (69%), diarrhea (64%), nausea (64%), decreased lymphocyte count (63%), fatigue (51%), alopecia (45%), constipation (37%), increased glucose (37%), decreased albumin (35%), vomiting (35%), decreased appetite (30%), decreased creatinine clearance (28%), increased alkaline phosphatase (28%), decreased magnesium (27%), decreased potassium (26%), and decreased sodium (26%).

In the ASCENT study (locally advanced or metastatic triple-negative breast cancer), the most common adverse reactions (incidence ≥25%) were fatigue, diarrhea, nausea, alopecia, constipation, vomiting, abdominal pain, and decreased appetite. The most frequent serious adverse reactions (SAR) (>1%) were neutropenia (7%), diarrhea (4%), and pneumonia (3%). SAR were reported in 27% of patients, and 5% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the ASCENT study were reduced neutrophils, leukocytes, and lymphocytes.

In the TROPiCS-02 study (locally advanced or metastatic HR-positive, HER2-negative breast cancer), the most common adverse reactions (incidence ≥25%) were diarrhea, fatigue, nausea, alopecia, and constipation. The most frequent serious adverse reactions (SAR) (>1%) were diarrhea (5%), febrile neutropenia (4%), neutropenia (3%), abdominal pain, colitis, neutropenic colitis, pneumonia, and vomiting (each 2%). SAR were reported in 28% of patients, and 6% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the TROPiCS-02 study were reduced neutrophils and leukocytes.

DRUG INTERACTIONS

UGT1A1 Inhibitors: Concomitant administration of TRODELVY with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38. Avoid administering UGT1A1 inhibitors with TRODELVY.

UGT1A1 Inducers: Exposure to SN-38 may be reduced in patients concomitantly receiving UGT1A1 enzyme inducers. Avoid administering UGT1A1 inducers with TRODELVY.

Please see full Prescribing Information, including BOXED WARNING.

About Gilead and Kite Oncology

Gilead and Kite Oncology are working to transform how cancer is treated. We are innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugate technologies and small molecules to cell therapy-based approaches, we are creating new possibilities for people with cancer.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress or complete clinical trials or studies within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing and additional clinical trials or studies, including those involving Trodelvy; uncertainties relating to regulatory applications and related filing and approval timelines, including such as the pending applications for Trodelvy in 1L mTNBC and potential applications for programs and/or indications currently under evaluation, and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; the possibility that Gilead may make a strategic decision to discontinue development of these programs and, as a result, these programs may never be successfully commercialized for the indications currently under evaluation; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.

Trodelvy, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

U.S. Prescribing Information for Trodelvy, including BOXED WARNING, is available at www.gilead.com.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

More News From Gilead Sciences, Inc.

In the latest close session, Enbridge (ENB - Free Report) was down 2.17% at $54.47. The stock's performance was behind the S&P 500's daily loss of 1.22%. Meanwhile, the Dow lost 0.98%, and the Nasdaq, a tech-heavy index, lost 1.35%.

Shares of the oil and natural gas transportation and power transmission company witnessed a loss of 1.95% over the previous month, beating the performance of the Oils-Energy sector with its loss of 6.85%, and underperforming the S&P 500's gain of 1.56%.

Analysts and investors alike will be keeping a close eye on the performance of Enbridge in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $0.44, marking a 6.38% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $11.22 billion, reflecting a 4.41% rise from the equivalent quarter last year.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $2.18 per share and a revenue of $51.3 billion, representing changes of +0.93% and +10.11%, respectively, from the prior year.

It's also important for investors to be aware of any recent modifications to analyst estimates for Enbridge. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.17% upward. At present, Enbridge boasts a Zacks Rank of #3 (Hold).

Digging into valuation, Enbridge currently has a Forward P/E ratio of 25.57. This valuation marks a premium compared to its industry average Forward P/E of 18.56.

The Oil and Gas - Production and Pipelines industry is part of the Oils-Energy sector. This industry, currently bearing a Zacks Industry Rank of 62, finds itself in the top 26% echelons of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Growth stocks continue leading the market higher. If you're an income investor shopping around for a new dividend-paying company, however, you might be a bit discouraged. That's because the market's relentless bullishness, which has driven the S&P 500 (^GSPC 1.44%) more than 100% higher since late 2022 (and up 16% just since late March), has also pared the index's dividend yield down to a record low of just over 1%. It suggests there are no great yields to be found anywhere.

Now dig deeper. They're out there, if you're willing to look a bit off the beaten path. A company called Enbridge (ENB +1.67%) fits the bill, with its forward-looking dividend yield of 5.1%.

Enbridge is oil-price-agnostic It's not a household name. There's a good chance, however, that your household regularly depends on the service it provides.

Enbridge owns over 18,000 miles' worth of natural gas and crude oil pipelines in the United States and Canada, moving 5.8 million barrels of oil and liquids every day. The company handles 30% of the crude drilled in North America, in fact, and 20% of the gas that the United States consumes.

Today's Change

(

1.67

%) $

0.92

Current Price

$

55.72

Yes, the energy business that's known for its increasingly volatile prices. Oil prices soared because of the military conflict with Iran, for instance, but are now plummeting on the International Energy Agency's call for a supply glut next year.

Here's the thing: Enbridge's business isn't built around the price of oil. It's essentially a tollbooth, charging other energy companies a fee based on the amount of natural gas and crude oil it's pushing through its pipelines. As long as North America continues consuming both, Enbridge's reliable revenue stream remains intact. This, of course, is ideal for supporting recurring dividend payments.

Image source: Getty Images.

And this demand is holding up. The United States Energy Information Administration reports the nation consumed nearly 2.78 trillion cubic feet of natural gas in March, up 1% year over year. As for crude oil, the EIA says the industry delivered 2% more of it in March of this year than it did in March of last year. This growth trend hasn't changed in the meantime, either, despite higher prices. Indeed, the U.S. Energy Information Administration predicts domestic demand for natural gas will reach record levels this year.

Now all of a sudden Enbridge's 31-year streak of annual dividend increases makes sense.

Perfect for its purpose Sure, there will come a time when the world weans itself from gas and oil in favor of more environmentally friendly renewables. That time isn't anywhere on the horizon, however. The International Energy Agency now doesn't expect the world to reach "peak oil" -- the point at which demand for crude oil stops growing and begins permanently shrinking -- until 2050, and even then we'll still need plenty of gas and oil past that point. There's good money to be made in the business in the meantime.

Even so, Enbridge is preparing for its inevitable distant future by investing in renewables like wind farms and solar power production facilities. The upside of this strategic shift is that it's got plenty of time to do it right.

The one arguable downside? There's not a lot of capital appreciation to be reaped here. Enbridge is first and foremost an income growth holding, albeit a good one.

The global economy is always adapting and evolving. As a result, companies need to remain innovative to stay ahead. Some companies have done an excellent job at keeping up with the times over the years, enabling them to grow their earnings and dividends for decades.

Enbridge (ENB +1.67%), ExxonMobil (XOM +0.91%), and NextEra Energy (NEE +0.41%) stand out for their dividend growth records. These energy companies have increased their payouts each year for more than three decades, which should continue for at least the next 10 years despite the sector's shift toward cleaner energy. That makes them ideal dividend stocks to buy and hold for the next decade.

Image source: Getty Images.

Steadily growing cleaner A decade ago, Enbridge got nearly three-quarters of its earnings from its oil and liquids pipeline segment, with the rest from lower-carbon energy (gas and renewable power). Today, more than half its earnings come from lower-carbon energy. Enbridge has invested heavily to grow its cleaner energy platforms through acquisitions and organic expansion projects.

The Canadian pipeline and utility company's shift to lower-carbon energy should continue in the coming decade. Enbridge ended the first quarter with 40 billion Canadian dollars ($28 billion) of secured growth capital projects in the backlog, which should enter service by the early 2030s. While its projects span liquids, gas, and renewables, the bulk of its spending is on cleaner energy. Meanwhile, it's pursuing about CA$50 billion ($35 billion) in additional growth capital projects, which it could approve by 2030, primarily in gas and renewables.

Today's Change

(

1.67

%) $

0.92

Current Price

$

55.72

These projects should support about 5% annual cash flow per share growth after this year. That will give Enbridge the fuel to continue increasing its more than 5%-yielding dividend in the coming decade. The company has now raised its payout for 31 consecutive years (in Canadian dollars).

Investing in the energy needed today and in the future ExxonMobil's current focus is on becoming an even more profitable oil and gas producer. It's investing heavily to develop its advantaged resources (lowest cost and highest margins) while also executing a multi-year structural cost-savings program. This strategy should grow its earnings capacity by $25 billion and cash flow by $35 billion by 2030, at the same margins and prices as in 2024. That's double-digit annual growth rates.

Today's Change

(

0.91

%) $

1.26

Current Price

$

139.73

The oil giant's plan would enable it to produce $145 billion in surplus cash during that period at $65 oil. That would give Exxon the funds to continue increasing its 3%-yielding dividend, which it has done for 43 consecutive years.

While Exxon's main focus is on producing oil and gas, the energy giant is also ramping up its investments in the energy sources we'll need in the future. It's developing carbon capture and storage, lithium, and biofuels projects. Additionally, Exxon is investing in new businesses, including Proxxima (polyolefin thermoset resin systems that outperform epoxy and polyurethane) and carbon materials. These businesses have the potential to reach $13 billion in earnings by 2040, while driving Exxon's growth for decades.

Accelerating the strategy NextEra Energy owns the country's largest electric utility and is a leading clean energy development company. It has invested heavily in renewable energy over the years, driving robust growth. NextEra has increased its nearly 3%-yielding dividend for more than 30 consecutive years, including delivering double-digit compound annual dividend growth over the last two decades.

Today's Change

(

0.41

%) $

0.35

Current Price

$

86.43

The company currently expects to invest between $295 billion and $325 billion in capex through 2032 to support surging U.S. power demand. That should give NextEra Energy the power to grow its adjusted earnings per share at a compound annual rate of more than 8% through 2032, with it highly likely to continue growing at that rate through at least 2035. That should support continued dividend increases, with NextEra targeting 6% compound annual growth in 2027 and 2028.

NextEra Energy recently pounced on the opportunity to accelerate its growth by agreeing to acquire Dominion Energy. The deal will create the world's largest regulated electric utility business and boost its growth rate to more than 9% annually through 2032, a rate it believes it can extend through 2035. The larger-scale company will be able to operate more efficiently, putting it in an even stronger position to capitalize on the AI power boom. As a result, it should have plenty of power to continue increasing its dividend in the decade ahead.

These dividends should continue rising in the coming decade Exxon, Enbridge, and NextEra Energy have already increased their dividends every year for decades. That upward trend should continue over the coming decade as they support the world's growing energy needs. Their combinations of higher yields and visible growth make them ideal dividend stocks to buy and hold for the next 10 years.

Enbridge (ENB - Free Report) ended the recent trading session at $55.74, demonstrating a +1.72% change from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 1.44%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq lost 2.22%.

Heading into today, shares of the oil and natural gas transportation and power transmission company had lost 5.58% over the past month, outpacing the Oils-Energy sector's loss of 7.14% and lagging the S&P 500's gain of 0.08%.

The investment community will be closely monitoring the performance of Enbridge in its forthcoming earnings report. The company is forecasted to report an EPS of $0.44, showcasing a 6.38% downward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $11.22 billion, up 4.41% from the prior-year quarter.

Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $2.18 per share and revenue of $51.3 billion. These totals would mark changes of +0.93% and +10.11%, respectively, from last year.

Investors should also note any recent changes to analyst estimates for Enbridge. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.29% lower within the past month. Enbridge currently has a Zacks Rank of #3 (Hold).

In terms of valuation, Enbridge is currently trading at a Forward P/E ratio of 25.16. This denotes a premium relative to the industry average Forward P/E of 17.85.

The Oil and Gas - Production and Pipelines industry is part of the Oils-Energy sector. Currently, this industry holds a Zacks Industry Rank of 92, positioning it in the top 38% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

© 0tvalo / Shutterstock.com

Our Realty Income (NYSE:O | O Price Prediction) call is constructive. The 24/7 Wall St. price target for Realty Income is $81.85, implying 31.66% upside from the $62.17 close on June 16, 2026. We rate the stock a buy with a 90% confidence level, which qualifies as high conviction inside our framework.

24/7 Wall St. Price Target Summary Metric Value Current Price $62.17 24/7 Wall St. Price Target $81.85 Upside 31.66% Recommendation BUY Confidence Level 90% A Net Lease Giant Quietly Reaccelerating Realty Income, branded as The Monthly Dividend Company, has woken up in 2026. Shares are up 12.68% year to date and 14.34% over the past year, trading roughly 2% below the 52-week high of $67.05 and well above the $53.32 low.

The Q1 2026 earnings report landed clean: AFFO per share of $1.13 rose 6.6% year over year, revenue hit $1.548 billion, and portfolio occupancy held at 98.9% with a 103.4% rent recapture rate.

Management raised 2026 AFFO guidance to $4.41 to $4.44 and lifted investment volume guidance to $9.5 billion from $8 billion, deploying capital at a 7.1% initial cash yield.

New private-capital vehicles, including the $1 billion Apollo joint venture and the $1.7 billion U.S. Core Plus cornerstone raise, are reshaping how Realty Income funds growth.

The Case for $90 and Higher Our bull case puts Realty Income at $90.14 one year out, a 44.99% total return. The catalysts are tangible. First, the private-capital flywheel. With third-party AUM at $3.10 billion and fee-earning equity of $1.331 billion, Realty Income is layering capital-light fee streams onto a stable rent base.

Second, global expansion across eight European countries beyond the U.K., plus a new $200M Mexican industrial portfolio, widens the addressable opportunity.

Third, dividend credibility: 114 consecutive quarterly increases and 670 monthly payouts support the 5.04% yield. CEO Sumit Roy said the raised outlook is “a testament to the unmatched scale, track record and operating capabilities of our global net lease enterprise.”

The Risks Worth Watching The bear case lands at $71.69, still a 15.32% return. The headwinds are real. Q1 2026 carried $129.3 million in impairment provisions, and full-year 2025 impairments totaled $471.3 million. Interest expense climbed to $1.13 billion in 2025 from $1.02 billion.

The top 20 clients account for 35.8% of annualized base rent, and reported P/E sits at a heady 55x. GAAP earnings understate cash power because real estate impairments are non-cash, and AFFO, the metric management and the dividend run on, grew 6.6%. Analyst sentiment skews cautious with 15 Holds against 8 Buys.

Realty Income Price Prediction 2026-2030 Our 24/7 Wall St. price target for Realty Income is $81.85 with a buy rating and 90% confidence. The tipping factor is the AFFO trajectory paired with a private-capital strategy that diversifies funding away from equity issuance.

The setup looks constructive for investors seeking a sub-1 beta income compounder with credible mid-single-digit AFFO growth. The thesis weakens if long rates climb materially from here, since cap-rate sensitivity would compress the multiple.

Year 24/7 Wall St. Price Target 2026 $71.45 2027 $83.02 2028 $98.80 2029 $114.00 2030 $126.81 These projections assume Realty Income continues compounding AFFO at the guided pace and that the private-capital platform scales. Significant upside or downside could result from material moves in long-term interest rates or unexpected tenant credit deterioration in the top-20 client roster.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Ten thousand dollars a month works out to $120,000 a year, an income stream that exceeds the roughly $68,359 in per-capita disposable personal income reported by the Bureau of Economic Analysis for the first quarter of 2026. For many retirees, that level of cash flow would support a lifestyle well above basic needs. The real question is how much capital it takes to generate that income without selling principal and what trade-offs come with reaching for higher yields.

A useful benchmark is the 10-year Treasury, which currently yields around 4.5%. Any dividend strategy must justify the additional risk it takes relative to that starting point. The higher the yield, the more important it becomes to understand what is driving it and whether that income can be sustained over time.

What a $10,000 Monthly Income Can Actually Buy A $10,000 monthly income provides a level of financial flexibility that exceeds the spending needs of many households. In much of the country, it can comfortably cover housing, healthcare costs, transportation, travel, and discretionary spending without requiring the sale of portfolio assets.

Taxes also matter. Qualified dividends from companies such as Johnson & Johnson or Procter & Gamble generally receive more favorable tax treatment than the ordinary income distributed by business development companies such as Main Street Capital Corporation. Depending on a retiree’s tax bracket and state of residence, that difference can materially affect the amount of income that ultimately reaches their bank account.

Tier 1: The 3% to 4% Sleep-At-Night Portfolio At a 3.5% blended yield, $120,000 divided by 0.035 equals roughly $3.43 million in capital. This is the dividend-growth tier, anchored by names like Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Procter & Gamble (NYSE:PG).

JNJ just raised its quarterly payout to $1.34, extending what is now 64 consecutive years of annual increases. P&G has paid a dividend every year since 1890 and lifted it for a 70th straight year. Yields here run roughly 2.3% on JNJ and 3.0% on PG, which is why the capital requirement is highest.

The tradeoff: low beta (JNJ’s is around 0.3), price appreciation alongside the income (JNJ is up 55% over the past year), and a payment stream that grows faster than inflation.

Tier 2: The 5% to 7% Middle Ground Push the blended yield to 6% and the capital required drops to $2 million. This is where high-dividend equities live. Verizon (NYSE:VZ) currently yields 6.2% with a forward P/E of 9. AbbVie sits closer to 3%, but its quarterly dividend has climbed from $0.40 in 2013 to $1.73 today, with Skyrizi sales up 31% last quarter funding further raises.

The tradeoff at this tier is slower dividend growth and more sensitivity to interest rates. Verizon’s total return over five years is just 8%. You collect a fatter check, but the principal does less work.

Tier 3: The 8% to 10% Maximum-Income Sleeve Stretch to a 10% blended yield and the capital requirement falls to $1.2 million. Realty Income (NYSE:O) yields about 5.4% and pays monthly, having just delivered its 670th consecutive monthly dividend at about $0.27 a share. Main Street Capital, a business development company, pays a $0.26 monthly regular plus a $0.30 quarterly supplemental, which together approach an 8% yield at recent prices.

Mortgage REITs, leveraged covered-call funds, and CLO equity products fill the rest of this tier and push yields toward 12%. The tradeoff is real: distributions can be cut, principal often erodes, and the supplemental portion of a BDC payout is the first thing to disappear in a recession.

Why Today’s Highest Yield May Produce Less Tomorrow A 3.5% yield that grows by 7% annually will roughly double its income stream within a decade. A 10% yield with no growth delivers more cash on day one, but exactly the same amount ten years later. The difference becomes significant over time. An income stream that starts at $120,000 and compounds through regular dividend increases can grow to roughly $240,000 by year ten without any additional capital. A static $120,000 income stream remains $120,000, while inflation steadily erodes its purchasing power.

This is the trade-off many retirees overlook. High-yield investments often maximize current income, while dividend growers maximize future income. Depending on the retiree’s time horizon, one may be far more valuable than the other.

Three Steps to Take Before Choosing a Yield Target Calculate your actual annual spending rather than your pre-retirement salary. Many retirees discover they need to replace closer to $80,000, which moves the entire capital requirement down a tier. Compare the ten-year total return of a dividend-growth name like JNJ (up 164% over the past decade) against a flat-yield BDC to see what compounding actually looks like in dollars. Model the tax bill at each tier in your specific bracket. The after-tax gap between a qualified-dividend portfolio and a BDC-heavy portfolio is often larger than the gap in headline yield.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Uncle Ralph owns a few rental properties, drives an old truck, and is rumored to be worth a fortune. At family gatherings, people joke about being remembered in the will. The problem is he may live another 20 years, spend more than expected, or leave the money somewhere else entirely.

The math suggests a better plan: become Uncle Ralph yourself. A dividend portfolio sized to your income target can generate cash every quarter, every year, without depending on someone else’s lifespan or estate plan.

Here is the engine behind the entire strategy. Take the annual income you want, divide by the yield your portfolio earns, and that is the amount of capital you need to build.

The Inheritance Reality Check The Uncle Ralph example is tongue in cheek, but it points to a real phenomenon. Many people who have not saved enough for retirement quietly assume an inheritance will eventually arrive from grandparents, parents, or another relative. They may never say it out loud, but the expected inheritance becomes a de facto retirement plan.

The problem is that most inheritances are smaller than imagined and arrive later than expected. Many are less than $50,000 and do not arrive until the heir is already in their 60s, long after the years when the money could have meaningfully changed a career path, accelerated retirement savings, or paid off a mortgage. Nursing homes, assisted living, hospice care, medical bills, and simple longevity can dramatically reduce an estate before it reaches the next generation. Some inheritances never materialize at all. Planning around one means tying your financial future to someone else’s spending decisions, lifespan, and estate plan.

The Capital Required to Become Your Own Rich Uncle So what does it actually take to become your own rich uncle? The table below shows the capital required to generate different levels of annual portfolio income at a range of yields.

Annual Income At 3.5% At 5% At 7% At 10% $12,000 $343,000 $240,000 $171,000 $120,000 $24,000 $686,000 $480,000 $343,000 $240,000 $60,000 $1,714,000 $1,200,000 $857,000 $600,000 $120,000 $3,429,000 $2,400,000 $1,714,000 $1,200,000 Every row is a real choice with real consequences. The 4.5% 10-year Treasury yield is the financial world’s gravitational pull. Yields far above it usually require more risk, while yields below it often depend on growth to make the math work over time.

The Conservative Tier: 3% to 4% Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) just raised its payout to $1.34 quarterly, its 64th consecutive annual increase. NextEra Energy is guiding to roughly 10% dividend growth through 2026 on the back of a 33 GW renewables backlog. Chevron (NYSE:CVX) pays $1.78 per quarter and returned over $5 billion to shareholders for the 16th straight quarter. Yields here sit near 3% to 4%, capital required is highest, and the principal generally appreciates alongside the income.

The Moderate Tier: 5% to 7% Net-lease REITs, preferred shares, investment-grade corporate bond funds, and high-dividend equity funds live here. Realty Income (NYSE:O) yields roughly 5% and just declared its 670th consecutive monthly dividend, with portfolio occupancy at 99%. The tradeoff is real: dividend growth slows, and inflation, currently running with Core PCE in the 90th percentile of its recent range, eats more of the income each year.

The Aggressive Tier: 8% to 12% Tobacco, midstream MLPs, business development companies, and mortgage REITs cluster here. Altria (NYSE:MO) pays $1.06 quarterly with the dividend up from $0.98 to $1.06 in 18 months. Energy Transfer distributes $0.3375 per unit after seven consecutive quarterly raises, though the K-1 tax form and MLP structure add complexity. Distributions can be cut, and principal can erode even while checks arrive.

What Monthly Contributions Actually Build Assuming an 8% total return with dividends reinvested, here is what consistent contributions become over 30 years:

$500 per month grows to roughly $745,000. At a 5% yield, that funds about $37,000 of annual income, replacing a part-time job for life. $1,000 per month grows to roughly $1.49 million. At 5%, that produces $74,000 a year, near the U.S. median household income. $2,000 per month grows to roughly $2.98 million. At 5%, that pays $149,000 annually, the income of a senior professional, without selling a share. Reinvested dividends do most of the heavy lifting in the final decade, which is why starting at 35 instead of 45 often doubles the result.

Three Things to Do This Week Pick your real income number based on what you spend each year, not what you earn. Divide it by 0.05 to see what a moderate-yield portfolio needs to hold. Set a monthly auto-contribution, even $250, into a brokerage account with dividend reinvestment switched on. The schedule matters more than the amount. Compare a 3.5% dividend-growth holding against a 10% high-yield holding over a 10-year total-return window. Let the compounding decide your tier. Finally, if you’re going to become your own rich uncle, casually mention at family gatherings that your latest checkup was excellent, longevity runs in the family, and the contents of your will are confidential.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

For many investors, real estate seems like the default path to passive income. Buy a rental, collect the checks, repeat. In reality, many landlords discover they have purchased a second job, complete with late-night phone calls, surprise repairs, insurance headaches, and months when the rent simply doesn’t arrive.

Instead, some investors build portfolios that generate income through dividends, interest, and other cash-producing investments. The goal is the same: a steady monthly paycheck. The difference is that it arrives without tenants, repairs, or vacancy worries.

Reaching $7,500 a month is not easy. But for investors with substantial savings, the numbers show it is possible to build a portfolio capable of producing roughly $90,000 a year in income without ever buying a rental property.

Capital Required at Four Yield Levels The equation is simple: target income divided by yield equals capital required.

3.5% yield: $90,000 / 0.035 = roughly $2,571,000. Dividend-growth equities and blue-chip aristocrats. Slow income today, faster compounding tomorrow. 5% yield: $90,000 / 0.05 = $1,800,000. Net-lease REITs, preferred shares, high-dividend equity funds. Higher current income, modest growth. 7% yield: $90,000 / 0.07 = roughly $1,286,000. Covered-call ETFs, business development companies, high-dividend funds. Flat growth, capped upside. 10% yield: $90,000 / 0.10 = $900,000. Mortgage REITs, leveraged option-income funds, high-yield bond CEFs. Maximum income, frequent distribution cuts and principal erosion. The 10-year Treasury sits near 4.5%, so $90,000 of risk-free income runs about $2 million. Yields below that must compete on growth; yields above it must justify the added risk.

What a Rental Portfolio Actually Costs At a 6% cap rate on residential property, $90,000 of net operating income requires roughly $1.5 million of real estate. That number hides the expenses that turn a 6% cap into a 4% cash yield: property taxes, insurance, vacancies usually budgeted at 5% to 8% of rent, repairs, capital expenditures (roofs, HVAC, water heaters), and a property manager taking 8% to 10% of gross rent.

Geographic concentration adds another layer. Five houses in one suburb share one weather event, one school district, one insurance market. Existing home sales at 4.17 million annualized sit in the soft zone, making appreciation a weaker tailwind than a decade ago.

Concrete Building Blocks Conservative core (3% to 4%). Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) trades near $235 with a 2.2% yield and a 64-year streak of annual hikes. PepsiCo (NASDAQ:PEP) pays 3.9% after raising the quarterly payout to $1.48. Utility names add regulated cash flow alongside these consumer staples.

Moderate yield (5% to 7%). Realty Income (NYSE:O) pays monthly at a 5.2% yield backed by 670 consecutive monthly distributions. Verizon (NYSE:VZ) yields 5.8% with a $0.7075 quarterly payout. Preferred shares and select BDCs round out the tier.

Aggressive (8% to 14%). Mortgage REITs, leveraged covered-call ETFs, and high-yield bond CEFs. Headline yields look generous until 10-year total returns are stacked against the conservative tier.

Why a Lower Yield Often Wins A portfolio yielding 3.5% may not look exciting next to one yielding 10%, but growth changes the equation. A $2.57 million portfolio generating $90,000 annually and growing its income 7% per year could be producing more than $160,000 a decade later. A $900,000 portfolio yielding 10% with no growth still pays the same $90,000. Inflation steadily erodes that purchasing power.

The Yield Trap Double-digit yields often come with hidden risks. Mortgage REITs, covered-call funds, and other high-yield investments can reduce distributions when market conditions change. When that happens, investors may suffer a double hit: lower income and a declining share price.

Where Real Estate Still Wins Real estate’s biggest advantage is leverage. A relatively small down payment can control a much larger asset, boosting returns when things go well. Rental properties also offer tax benefits through depreciation, and rents often rise with inflation. Investors with strong local knowledge and renovation skills can sometimes create value that a portfolio of stocks and bonds cannot.

The trade-off is simple: those advantages usually require active work. The investor seeking a truly hands-off income stream may prefer a portfolio that pays without tenants, repairs, or late-night phone calls.

What to Do This Week Calculate actual spending rather than replacing a paycheck. Many retirees only need to replace $60,000 of spending, which moves the conservative tier from $2.57 million to roughly $1.71 million. Compare 10-year total returns (price plus reinvested dividends) of a 3.5% dividend-growth fund against a 10% covered-call fund before committing to a tier. Within five years of retirement, model the tax impact of qualified dividends versus REIT ordinary income in your bracket. The wrong tier in the wrong account can erase a full percentage point of yield.

First-in-human Phase 1 study in 56 healthy participants demonstrated KIT2014’s safety and tolerabilityKIT2014 is being developed as an inhalation therapy for respiratory diseases including chronic obstructive pulmonary disease (COPD), non-CF bronchiectasis (NCFB) and cystic fibrosis (CF)KIT2014’s unique mode of action improves respiratory symptoms by promoting bronchodilation and reducing lung inflammation
TURIN, Italy, June 19, 2026 (GLOBE NEWSWIRE) -- Kither Biotech Pty Ltd and Kither Biotech srl, a clinical-stage biopharmaceutical group of companies developing innovative therapies for respiratory diseases, today announced the successful completion of their Phase 1 clinical study of KIT2014 in healthy participants.

“We are pleased to report the successful completion of this first-in-human Phase 1 study with KIT2014, a significant milestone for Kither Biotech,” said Dr. Dimitrios Goundis, CEO of Kither Biotech. “The study results demonstrate KIT2014’s favourable safety and tolerability profile. The unique ability of KIT2014 to increase cAMP in different airway cell types offers the potential for multiple therapeutic benefits, including bronchodilation and anti-inflammatory effects. We look forward to advancing the clinical development of KIT2014, to assess its therapeutic potential in patients with respiratory diseases including COPD, NCFB and CF.”

“We are delighted that this first-in-human study has successfully demonstrated that inhaled KIT2014 was safe and well tolerated across all dose levels evaluated, with no measurable systemic exposure,” said Anita van der Meer, Director of Kither Biotech Pty Ltd. “These findings support the continued clinical development of KIT2014 and provide a strong foundation for advancing into patient studies in COPD, where we aim to further explore its unique multimodal mechanism of action and potential to address important unmet medical needs.”

KIT2014 is a novel cell-permeable peptide delivered via inhalation, which is designed to address multiple pathological pathways common to a number of major respiratory diseases. The drug, which consists of 42 amino acids, acts to promote bronchodilation and reduce lung inflammation. It does this through balanced dual inhibition of the enzymes phosphodiesterase 3 and 4 (PDE3/4), which increases local concentrations of the key signalling molecule cAMP (cyclic adenosine monophosphate). KIT2014 is being developed for a number of respiratory diseases including COPD, NCFB and CF.

Key findings of the Phase 1 study were that:

Treatment with KIT2014 at doses ranging from 0.1 mg to 2 mg daily for up to 7 days was safe and well tolerated.Blood plasma levels of KIT2014 were below the limit of detection at all dose levels, both in the single ascending dose (SAD) and multiple ascending dose (MAD) parts of the study, indicating direct administration to the lungs results in very low systemic exposure. This Phase 1 clinical trial was a double-blind, randomised, placebo-controlled, two-part dose escalation study (single ascending dose and multiple ascending dose), conducted in 56 healthy participants. The primary objective was to evaluate the safety and tolerability of KIT2014. The secondary objective was to evaluate blood plasma pharmacokinetics.

For more information, visit clinicaltrials.gov NCT06659757.

Kither Biotech’s leadership team will be attending the BIO International Convention in San Diego, US, from 22–25 June 2026. The team will be available to meet investors, pharmaceutical and biotech partners, research analysts, and potential collaborators. To schedule a meeting, please contact: [email protected].

Contact Information

Kither Biotech
Dr. Dimitrios Goundis
Chief Executive Officer
Email: [email protected]

Optimum Strategic Communications
Stephen Adams / Aoife Minihan / Ben Cowe
Tel: +44 203 821 6420
Email: [email protected]

Notes for editors

About Kither Biotech
Kither Biotech is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s lead program, KIT2014, represents a novel approach to treating respiratory conditions by targeting multiple respiratory disease pathways, simultaneously. Kither Biotech has successfully raised $26 million to date from leading life sciences investors including Claris Ventures, 2Invest, 3B Future Health, CDP Venture Capital, Italian Angels for Growth, Club degli Investitori, Ersel and ACE Venture. For more information, please visit www.kitherbiotech.com and follow us on LinkedIn.

About KIT2014
KIT2014 is a first-in-class inhaled peptide therapy that targets multiple pathways critical to respiratory disease pathophysiology. By equally inhibiting both phosphodiesterase 3 and 4 (PDE3/4) and enhancing cyclic adenosine monophosphate (cAMP) levels in airway cells, KIT2014 improves airway flow via relaxation of airway smooth muscle and bronchodilation, reduces epithelial and neutrophil-driven inflammation, and increases CFTR gating to improve chloride ion transport and airway mucus hydration and clearance. Inhaled delivery allows direct targeting of the lungs while minimising systemic exposure, potentially offering an improved safety profile compared to similar therapies with greater systemic exposure and side effects.

About KIT2014’s target indications
KIT2014 has the potential to address significant unmet needs across respiratory diseases including COPD, NCFB and CF.

Chronic obstructive pulmonary disease (COPD) affects more than 400 million people globally, and continues to be the third largest cause of death worldwide. It is an irreversible airflow-limiting disease primarily caused by smoking and environmental exposures, characterised by chronic respiratory symptoms, and progressive decline in lung function. The underlying pathology is driven by inflammation leading to small airway remodelling, and parenchymal destruction.

Non-CF bronchiectasis (NCFB) impacts approximately 500,000 people in the US and a similar number in Europe, with limited treatment options available. It is a chronic airway disease characterised by permanent dilation of the bronchi, leading to cough, sputum production, and recurrent infective exacerbations. The disease creates a vicious cycle of mucus accumulation, infection and neutrophilic inflammation.

Cystic fibrosis (CF) affects approximately 130,000 people worldwide and, despite advances in CFTR modulators, many patients continue to experience persistent inflammation and recurrent infections. It is a life-limiting genetic disease caused by mutations in the CFTR gene, leading to defective chloride ion transport in multiple organ systems. In the lungs, this results in thick, sticky mucus buildup promoting chronic bacterial infections, persistent inflammation and decline in lung function.

Key Takeaways CF and NTR benefit from strong agricultural markets, tight supplies and higher fertilizer pricing.CF benefits from tight global nitrogen markets, strong pricing and strong cash flows.Nutrien is boosting potash output, expanding through acquisitions and advancing cost reductions. CF Industries Holdings, Inc. (CF - Free Report) and Nutrien Ltd. (NTR - Free Report) are two of the biggest players in the fertilizer space. The underlying strength of the agricultural market and attractive farm economics are spurring demand for fertilizers globally. Farmer economics remain favorable in most global growing regions due to strong crop demand and affordable inputs.

Supportive farmer economics, improved affordability and low inventory levels are driving potash demand globally. The phosphate market is also benefiting from low producer and channel inventories. Demand for nitrogen fertilizer remains strong in major markets such as North America, India and Brazil. Strong demand and supply tightness have also led to an uptick in fertilizer prices.

Let’s dive deep and closely compare the fundamentals of these two major fertilizer producers to determine which one is a better investment option in the current environment.

The Case for CF IndustriesCF Industries is capitalizing on the growing global demand for nitrogen fertilizers, driven by strong agricultural activity.  Global nitrogen requirement is expected to remain strong in the near future due to recovering industrial demand and farmer economics.

High levels of corn-planted acres in the United States should drive demand for nitrogen. Demand in North America is expected to be fueled by favorable farm economics.  In Brazil, demand for urea is likely to remain healthy in 2026, driven by higher corn plantings. In India, low inventory levels, reduced domestic production and undelivered volumes due to the Iran war are likely to lead to a greater requirement. The company expects India’s urea imports to rise year over year in 2026, potentially reaching 10-12 million metric tons.

CF, on its first-quarter call, said that the global nitrogen market will remain tight in 2026 due to strong demand, geopolitical disruptions and constrained natural gas availability. The Middle East conflict has further tightened the global nitrogen supply-demand balance.

Higher nitrogen prices have also contributed to a boost in CF Industries’ revenues. In the first quarter, net sales rose roughly 19% year over year on pricing strength. The average selling prices for the company’s core products increased from the prior year, driven by supply disruptions and strong global nitrogen demand. Looking ahead, CF should continue to benefit from favorable pricing trends.

CF Industries continues to focus on enhancing shareholder value by utilizing its strong cash flow, thanks to strong operational performance, strategic execution and supportive nitrogen industry fundamentals.  For full-year 2025, net cash from operating activities was $2.75 billion, while free cash flow was $1.79 billion, up roughly 21% and 24% year over year, respectively. The company’s cash and cash equivalents were roughly $2 billion at the end of the first quarter. Net cash provided by operating activities was $496 million for the quarter.

The company is efficiently converting adjusted EBITDA to free cash flow. Its full-year 2025 free cash flow to adjusted EBITDA conversion rate was 62%, outpacing sector averages. The same for the first quarter was 51%.

CF returned $1.7 billion to its shareholders in 2025. It repurchased 16.6 million shares for $1.34 billion during 2025. Since the commencement of its current $2 billion buyback program in October 2025, CF Industries has bought back 3.6 million shares for around $293 million. CF offers a dividend yield of roughly 1.9% at the current stock price. It has a payout ratio of 19%. CF has a five-year annualized dividend growth rate of 12.9%.

The Case for Nutrien  Nutrien is well-placed to benefit from higher demand for fertilizers, backed by the strength in global agriculture markets. It is seeing healthy fertilizer demand in its major markets. Tight inventories are expected to support crop commodity prices.

NTR saw record potash sales volumes in the first quarter of 2026, driven by low inventory levels and favorable potash affordability, especially in key offshore markets. The company maintained its global potash shipment forecast of 74-77 million tons for 2026 and sees relatively tight potash fundamentals through the year. It is also increasing production from its low-cost North American operations to meet rising demand.

Nutrien should also gain from acquisitions and increased adoption of its digital platform. It continues to expand its footprint in Brazil through acquisitions. It is expected to continue pursuing targeted opportunities in its core markets. The company expects to utilize part of its free cash flow for incremental growth investments, including tuck-in acquisitions in the retail business.

Cost and operational efficiency initiatives are also expected to aid the company’s performance. NTR remains focused on lowering the cost of production in the potash business. It has announced several strategic actions to reduce its controllable costs and boost free cash flow. It surpassed the $200 million annual cost savings target for 2025, achieving it a year earlier than its initial target. It expects sustained cost-reduction efforts across all geographies to aid margin improvement in 2026.

NTR has a strong balance sheet, enabling it to finance its strategic growth investment, pay down debt and drive shareholder value. It returned $409 million to its shareholders in the first quarter through dividends and share repurchases. Nutrien offers a dividend yield of roughly 3.4% at the current stock price. It has a payout ratio of 48% and a five-year annualized dividend growth rate of 4.1%.

NTR, however, remains exposed to a volatile input cost environment amid supply tightness. Nutrien uses sulfur, ammonia and natural gas as key inputs. Supply disruptions from Russia amid the war with Ukraine, exacerbated by the Middle East conflict, contributed to the rise in input prices. Plant shutdowns and maintenance also resulted in a tight supply of these inputs, which, coupled with strong demand, pushed up their prices. Tight global sulfur supply, higher benchmark sulfur prices and ongoing supply-chain constraints continued to increase phosphate production costs.

The company saw higher sulfur input costs in the first quarter, leading to a higher cost of goods sold per ton in the phosphate businesses, hurting margins. It expects further pressure on phosphate margins in the second quarter, resulting from higher sulfur and ammonia costs.

Price Performance and Valuation of CF & NTRThe CF stock is up 33.1% year to date, while NTR has gained 1.9% compared with the Zacks Fertilizers industry’s rise of 8%.

Image Source: Zacks Investment Research

CF is currently trading at a forward 12-month earnings multiple of 7.26. This represents a roughly 34.8% discount when stacked up with the industry average of 11.14X.

Image Source: Zacks Investment Research

NTR is currently trading at a forward 12-month earnings multiple of 11.17, above CF and the industry.

Image Source: Zacks Investment Research

How the Zacks Consensus Estimate Compares for CF & NTRThe Zacks Consensus Estimate for CF’s 2026 sales implies a year-over-year rise of 22.8%. The same for EPS suggests a 83.1% year-over-year increase. The EPS estimates for 2026 have been trending higher over the past 60 days.

Image Source: Zacks Investment Research

The consensus estimate for NTR’s 2026 sales and EPS implies a year-over-year rise of 8% and 31.4%, respectively. The EPS estimates for 2026 have been trending northward over the past 60 days.

Image Source: Zacks Investment Research

CF or NTR: Which Stock Holds the Edge?Both CF and Nutrien are benefiting from strong global demand, thanks to the favorable agricultural conditions and supportive farm economics. Higher fertilizer prices are also expected to aid their performance. Both remain committed to boosting shareholder returns. CF appears to have an edge over NTR due to its more attractive valuation and higher dividend growth rate. In addition, CF’s higher earnings growth projections suggest that it may offer better investment prospects in the current market environment.

CF currently carries a Zacks Rank #2 (Buy), while NTR has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

LyondellBasell Industries N.V. is downgraded to Hold after 2025 annual and FQ1 2026 updates reveal mixed profitability and persistent growth uncertainty. LYB is exiting oil refining and closing legacy plants, aiming to focus on higher-margin polymer segments and proprietary MoReTec recycling technology. The reinvention show long-term promise and is supported by several positive forces.

4:15pm: Big Tech selloff US stocks finished mixed on Monday as steep losses in some of the market's biggest technology names outweighed gains across much of the broader market.

The Dow Jones Industrial Average rose 148 points, or 0.3%, to close at 51,713, supported by optimism surrounding geopolitical developments and strength in non-technology sectors. However, the S&P 500 slipped 28 points, or 0.4%, to 7,473, while the Nasdaq dropped 351 points, or 1.3%, to 26,167.

Technology stocks were at the center of the selling pressure. Alphabet fell more than 5% after concerns emerged over talent departures within its artificial intelligence division. Amazon declined roughly 4%, while Meta Platforms lost about 2%, adding to the drag on the broader market.

SpaceX was among the day's biggest losers, tumbling as much as 14% and hitting its lowest level since the company's IPO earlier this month, further weighing on investor sentiment toward high-growth technology shares.

Despite the weakness in megacap tech, market breadth was generally positive, helping lift the Dow into positive territory. Still, the sharp declines in some of the market's largest companies proved too much for the S&P 500 and Nasdaq to overcome, leaving the major indexes divided by the closing bell.

3:40pm: Proactive news headlines HIVE Digital Technologies Ltd (TSX:HIVE, NASDAQ:HIVE, FRA:YO0, BVC:HIVECO) completed its first AI research project using GPUs in Paraguay in collaboration with Columbia University researchers, with the study submitted to the NeurIPS machine learning conference. Argentina Lithium & Energy Corp (TSX-V:LIT, OTCQX:LILIF) announced the retirement of vice president exploration Miles Rideout, who helped advance the company's Argentine lithium projects, including the first resource estimate for Rincon West. Blockmate Ventures Inc (TSX-V:MATE, OTCQB:MATEF, FRA:8MH) plans to raise up to $750,000, and potentially $1 million through oversubscriptions, via a non-brokered private placement of units priced at $0.05 each. American Resources Corp (NASDAQ:AREC) said its subsidiary ReElement Technologies is advancing construction of its rare earth and critical minerals refining campus in Marion, Indiana, with initial germanium production targeted for the third quarter of 2026. 2:30pm: Market movers Alphabet Inc (NASDAQ:GOOG) shares fell 5.5% after the company lost key AI researcher Noam Shazeer to OpenAI, fueling investor concerns about talent retention and its AI strategy. Definium Therapeutics shares surged about 53% after the company reported positive Phase 3 trial results for its LSD-based depression treatment DT120, which met its primary and key secondary endpoints. Lucid Group Inc (NASDAQ:LCID) announced plans to cut roughly 18% of its U.S. workforce as part of a restructuring effort expected to generate about $158 million in annual cost savings. HIVE Digital Technologies Ltd (TSX:HIVE, NASDAQ:HIVE, FRA:YO0, BVC:HIVECO) completed its first AI research project using GPUs in Paraguay in collaboration with Columbia University Department of Industrial Engineering and Operations Research, with the research submitted to the NeurIPS conference. Abbvie Inc (NYSE:ABBV) agreed to acquire Apogee Enterprises (NASDAQ:APOG) for approximately $10.9 billion in cash, expanding its pipeline of treatments for inflammatory and immunological diseases. Getty Images shares jumped about 118% after the company signed a multi-year agreement with OpenAI to integrate Getty's licensed image library into ChatGPT's search and visual response capabilities. 12:50pm: Will oil supply disruptions ease? Oil's recent rebound appears to be fading as traders become more confident that supply disruptions tied to U.S.-Iran tensions will ease, says IG's Chris Beauchamp.

"Despite a stormy weekend of talks in Switzerland and threats from the White House, it seems some progress was actually made between the two sworn enemies," Beauchamp noted Monday. 

"Compared to recent days, passage through Hormuz seems to have returned to a more reasonable level too, giving hope for consumers that petrol prices will continue to come down.”

11:45am: Week ahead Wall Street enters the final full week of June with investors juggling inflation, artificial intelligence and the health of the banking sector.

After last week's Federal Reserve meeting under new Chair Kevin Warsh, attention now shifts to a busy slate of economic data, corporate earnings and Fed commentary that could help shape expectations for interest rates and market direction heading into the second half of the year.

The week's biggest corporate event comes Wednesday when Micron Technology Inc (NASDAQ:MU) (Micron Technology Inc (NASDAQ:MU)) reports quarterly results. The memory-chip maker has emerged as one of the biggest winners of the AI boom, making its outlook closely watched across the semiconductor industry.

Investors will be looking for updates on demand for high-bandwidth memory chips used in AI servers, as well as management's expectations for datacenter spending.

The macroeconomic highlight arrives Thursday with the release of the core Personal Consumption Expenditures index, the Fed's preferred measure of inflation.

Economists expect annual core PCE inflation to rise to about 3.4%, a reading that could reinforce concerns that price pressures remain stubbornly high.

10:50am: AbbVie snaps up Apogee for nearly $11B Abbvie Inc (NYSE:ABBV) (Abbvie Inc (NYSE:ABBV)) announced that it will acquire Apogee Therapeutics (NASDAQ:APGE) in an all-cash transaction valued at approximately $10.9 billion, adding a pipeline of clinical-stage therapies for inflammatory and immunological diseases, including atopic dermatitis and asthma.

Under the terms of the definitive agreement announced Sunday, AbbVie will acquire all outstanding Apogee shares for $135.11 per share in cash.

Shares of AbbVie added 4.5% at $226 on the news, while Apogee shares surged 47% to about $133.

9.55am: Dow up but Nasdaq flat US stocks were showing a familiar split in opening trades, with the Dow Jones opening up 0.5% as investors rotate into cyclical and defensive blue chips including JPMorgan, Goldman Sachs, Caterpillar, UnitedHealth and Amgen.

The S&P 500 climbed just over 0.3%, led by gains for Super Micro Computer, ON Semiconductor, AbbVie, Micron, Dell and SanDisk. 

The Nasdaq was flat as investors take profits in technology names. ARM, Qualcomm, AppLovin, Marvell, and Palantir are among the biggest fallers, with several high-growth stocks down more than 2%.

Among the tech megacaps, Alphabet lost more than 3%, while Amazon dropped 1.8%, while Meta and Microsoft fell in early trade. Nvidia and Apple were higher. 

SpaceX fell back again, down 7.8% to under $171, still above its $135 IPO price but well off its early $225.64 high. 

9.15am: Former Fed chief Greenspan dies at 100 Alan Greenspan, who chaired the Federal Reserve from 1987 to 2006 under four US presidents, has died aged 100.

Greenspan oversaw Wall Street's 1987 crash, the dotcom boom and bust, and much of the period later dubbed the "Great Moderation" of steady growth and low inflation.

The Fed has put out a statement, saying he "helped establish the credibility that remains one of the Federal Reserve’s most important assets” in a statement", while admirers credited him with helping steer the US economy through nearly two decades of expansion.

His reputation was dented after the 2008 financial crisis, when regulators and politicians blamed decades of deregulation and faith in banks' ability to police themselves for helping to create the conditions for the collapse.

The former Fed chair later admitted he had "made a mistake" in believing financial institutions could effectively self-regulate, although he resisted attempts to hold him chiefly responsible for the crisis.

8.45am: Wall Street futures point higher US futures were pointing higher at the start of the week as investors return from the Juneteenth holiday weekend, with technology stocks expected to lead gains despite lingering uncertainty over the Middle East and the prospect of further Federal Reserve tightening.

Dow Jones futures were up 96 points, or 0.2%, while S&P 500 futures edged 0.1% higher and Nasdaq futures outperformed, rising 0.4%.

The upbeat mood follows a mixed session in Asia., with Japan's Nikkei climbing 1.6% to another record close, while China's Shanghai Composite gained 1.8%.

South Korea's Kospi rose 0.7% as memory chip maker SK Hynix jumped to a fresh all-time high and overtook Samsung as the country's most valuable listed company.

Markets continue to digest developments in the Middle East after Iran said talks with the US had made "major progress".

Oil prices initially jumped after reports that Tehran had moved to close the Strait of Hormuz, only to retreat as optimism over negotiations returned. WTI crude is down 1.15 at $75.75, still well above the sub-$60 levels seen at the start of the year.

Investors are also adjusting to a more hawkish Federal Reserve, with markets now pricing an 89% chance of at least one further rate increase before the end of 2026, with no expectation of a rate cut.

BofA Global Research is forecasting a further 75 basis points of US rate hikes this year.

That typifies a wider shift has helped support the dollar and pushed Treasury yields higher. 

Deutsche Bank argues the recent US-Iran progress has failed to spark a bigger market rally because of the Fed's hawkish shift under new chief Kevin Warsh, pushing real Treasury yields to their highest level in more than a year.

Strategist Henry Allen also notes that the S&P 500 had already surged 16% over April and May, leaving limited room for further gains, while tanker traffic through the Strait of Hormuz remains "at just a fraction of its pre-conflict levels"

The week ahead brings results from FedEx and Carnival, Micron's closely watched earnings on Wednesday, the Fed's annual bank stress tests and the latest reading of core PCE inflation.

On June 22, 2026, AbbVie Inc ABBV shares rose 6.2% to a current price of $230.01. This increase comes amidst a 52-week trading range of $181.73 to $244.81, indicating strong recent performance as the stock has gained 28.2% over the past year.

GF Value™ verdict: Current price is $230.01, compared to GF Value™ of $211.20, indicating the stock is 8.9% overvalued.GF Score™: 82/100, signifying a strong overall rating.Most notable signal: Financial Strength rated at 4/10 suggests potential weaknesses in the company's financial stability. Is ABBV Overvalued or Undervalued? According to GF Value™, AbbVie Inc ABBV is currently overvalued with a market price of $230.01 compared to its estimated fair value of $211.20. This results in a margin of safety of -8.9%, indicating that the stock may not provide adequate downside protection at its current price. The GF Valuation label categorizes ABBV as "Fairly Valued," which suggests that while the stock is trading above its calculated intrinsic value, it does not necessarily imply that it is a poor investment; rather, it may indicate that the market has high expectations for the company's future growth and profitability.

Investing in an overvalued stock carries risks, particularly in a volatile market where corrections can occur. Therefore, potential investors should be cautious and consider the possibility that the stock price may decline if the company's performance does not meet market expectations.

How Does ABBV's Valuation Compare to Its History? MetricCurrentHistorical P/E (TTM)113.3x42.5x Forward P/E16.1xN/A The current P/E ratio of 113.3x is significantly above its 5-year median P/E of 42.5x, indicating that the stock is trading at a premium relative to its historical valuation. This analysis agrees with the GF Value™ verdict that AbbVie is currently overvalued, as the elevated P/E suggests that investors are paying a higher price for each dollar of earnings compared to historical averages.

What Does ABBV's GF Score™ Tell Us? MetricRating GF Score™82/100 Financial Strength4/10 Profitability8/10 Growth7/10 Valuation7/10 Momentum7/10 The GF Score™ of 82/100 reflects a strong overall rating, with particularly high scores in Profitability (8/10) and Growth (7/10). However, the Financial Strength rating of 4/10 indicates potential weaknesses in the company's balance sheet that could affect its long-term sustainability. The solid profitability and growth metrics suggest that while AbbVie can generate earnings and expand, the financial stability may not be as strong, warranting close monitoring.

What Are Insiders Doing with ABBV Stock? Over the past three months, there have been no insider transactions reported for AbbVie Inc ABBV . The lack of insider activity may suggest that management does not view the current stock price as a significant opportunity for buying or selling, which can be interpreted as a neutral signal regarding the company's outlook from those closest to its operations.

What This Means for Investors Based on the GF Value™ assessment, AbbVie Inc ABBV is currently overvalued, trading at a price of $230.01 against a fair value estimate of $211.20. Investors should be cautious of the potential risks associated with an overvalued stock, especially in light of the company's financial strength rating and the elevated P/E ratio compared to historical norms.

For the complete analysis, visit the AbbVie Inc ABBV stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is ABBV's GF Score™?

ABBV's GF Score™ is 82/100, indicating a strong overall assessment based on various financial metrics and historical performance.

Is ABBV overvalued or undervalued?

ABBV is currently overvalued, with a current price of $230.01 compared to a GF Value™ estimate of $211.20, reflecting a margin of safety of -8.9%.

What is ABBV's P/E ratio?

ABBV's current P/E (TTM) is 113.3x, which is significantly above its 5-year median P/E of 42.5x, suggesting that the stock is trading at a premium compared to its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

AbbVie (ABBV +2.06%) was one of the livelier stocks in Monday’s trading session. It was also one of the better-performing equities, gaining more than 6% that day. Much of this was due to a splashy new acquisition that will strengthen its already considerable presence in a lucrative segment of the pharmaceutical market.

A monster immunology playBefore market open, AbbVie and Apogee Therapeutics (APGE +0.25%) announced they had signed a definitive agreement for AbbVie to acquire its peer.

Image source: Getty Images.

The deal, valued at roughly $10.9 billion, obligates AbbVie to pay Apogee stockholders $135.11 per share in cash. The two companies did not hesitate to mention that their boards of directors have both unanimously approved the transaction.

It is still subject to the approval of Apogee shareholders. That, however, appears inevitable, as the agreed purchase price is nearly 47% above the stock’s closing price on the previous trading day. The transaction will also have to be cleared by the relevant regulatory authorities.

AbbVie and Apogee said they expect it to close in the third quarter of this year.

Promising pipelineApogee is a clinical-stage biotech with several promising investigational programs — hence the premium that AbbVie was willing to pay to acquire it.

The company has developed two monotherapies and combined them with secondary mechanisms to create a pair of combination drugs. All target the proteins that power chronic immune and inflammatory disorders.

Its leading drug program (and the most advanced in the pipeline) is zumilokibart, a monoclonal antibody currently in Phase 2 testing for moderate-to-severe atopic dermatitis (a.k.a. eczema), and in Phase 1b for asthma. It has done extremely well in its trials for eczema.

What’s arguably most promising about zumilokibart is that its effects are relatively long-lasting; patients would only need to take it once every three to six months, compared to once every two weeks for treatments currently on the market. So if it’s ultimately approved, it should be very competitive.

Another plus for the drug is its potential versatility, as it’s also being developed for asthma and eosinophilic esophagitis (allergic inflammation of the esophagus).

The company’s APG279, meanwhile, is a similarly versatile drug currently being developed for the treatment of eczema. If successfully brought to market, it would compete with the highly successful Dupixent marketed by Sanofi and Regeneron Pharmaceuticals.

Finally, there’s the monotherapy APG333, which is combined with zumilokibart in another investigational drug, APG273. Both currently target asthma and COPD.

Ever-ascending AbbVieIn the joint press release, AbbVie and Apogee said their deal is expected to be accretive to the former’s earnings per share (EPS) not in accordance with generally accepted accounting principles (GAAP) starting in 2032.

Given that Apogee hasn’t yet entered Phase 3 trials for zumilokibart, that’s a fairly quick turnaround for a clinical-stage asset.

I feel this acquisition is one of the better and more promising ones for AbbVie, given the obvious strength and potential of Apogee’s pipeline. AbbVie continues to grow in clever ways, both through its proprietary development efforts and through biotech acquisitions.

Today's Change

(

2.06

%) $

4.75

Current Price

$

234.76

That said, Apogee isn’t coming cheap; The Wall Street Journal cited a Citigroup analysis stating that in purchasing it, AbbVie will take a $0.14-per-share hit to its non-GAAP (adjusted) EPS this year, and $0.46 per share in 2027.

Still, the consensus analyst estimates for the two years stand at $14.24 and $16.25, respectively, so I don’t think the stock will suffer. I also believe AbbVie’s dividend, currently yielding more than 3%, won’t come under pressure.

All in all, then, I think the Apogee deal boosts the buy case for AbbVie’s already-attractive stock

SKYRIZI® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis1 Approval was based on the pivotal Phase 3 OptIMMize-1 and OptIMMize-2 trials which include a new 55 mg pre-filled syringe to support weight-based dosing for patients weighing less than 40 kg1 Nearly a third of people living with psoriasis develop symptoms before the age of 18, often getting lesions on highly visible areas2,3 , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI® (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque psoriasis who are candidates for systemic therapy. The approval includes a new 55 mg pre-filled syringe (PFS) to support weight-based dosing for patients weighing less than 40 kg.1

"Plaque psoriasis in children carries its own clinical complexity and urgency to provide additional efficacious treatment options," said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. "Today's approval of SKYRIZI for pediatric psoriasis patients is a meaningful step forward for millions worldwide who are looking for additional treatment options to better manage this chronic disease in their formative years."

Nearly a third of people living with psoriasis develop symptoms before the age of 18, often getting lesions on highly visible areas.2,3 Because children often have facial or scalp involvement, the early-onset of psoriasis increases the risk of school absenteeism, potential social stigma, and development of other comorbidities.3,4 Despite the significant impact of the disease on children's quality of life, nearly 70% of pediatric patients rely solely on topical therapies.5

Data Supporting the EC Approval

The EC's approval of SKYRIZI in pediatric patients is supported by clinical data from the Phase 3 OptIMMize-1 pediatric psoriasis program (NCT04435600), including data from two lead-in pharmacokinetic cohorts: a randomized efficacy assessor-blinded, active-controlled cohort (12 to <18 years), and a single-arm, open-label cohort (6 to <12 years), in addition to the Phase 3 OptIMMize-2 open-label extension study (NCT04862286). The safety profile in pediatric patients (n=137) treated with SKYRIZI was consistent with that observed in adults with moderate to severe plaque psoriasis, with no new safety signals observed.1

"Particularly for pediatric psoriasis patients, early diagnosis and management can prevent symptoms from worsening and improve quality of life in the long-term," said Nina Magnolo, M.D., Department of Dermatology, University Hospital of Münster, and lead investigator of the OptIMMize-1 study. "The EC's approval of risankizumab provides younger patients with more options including weight-based dosing and allows physicians to address unmet clinical needs of children living with moderate to severe psoriasis with confidence."

About SKYRIZI® (risankizumab)
SKYRIZI is an interleukin (IL)-23 inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases. SKYRIZI is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis in adults.

EU Indications and Important Safety Information about Skyrizi® (risankizumab)1

Indications

Skyrizi (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.

Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).

Skyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Skyrizi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Important Safety Information

Risankizumab is contraindicated in patients hypersensitive to the active substance or to any of the excipients, and in patients with clinically important active infections (e.g. active tuberculosis).

Risankizumab may increase the risk of infection. In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, risankizumab should be used with caution. Treatment with risankizumab should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.

Patients treated with risankizumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops such an infection or is not responding to standard therapy for the infection, the patient should be closely monitored and risankizumab should not be administered until the infection resolves.

Prior to initiating treatment with risankizumab, patients should be evaluated for tuberculosis (TB) infection. Patients receiving risankizumab should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating risankizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.

Prior to initiating therapy with risankizumab, completion of all appropriate immunisations should be considered according to current immunisation guidelines. If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab. Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment.

Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of risankizumab. If a serious hypersensitivity reaction occurs, administration of risankizumab should be discontinued immediately and appropriate therapy initiated.

The most frequently reported adverse reactions were upper respiratory infections (13% in psoriasis, 15.6% in Crohn's disease and 26.2% in ulcerative colitis).

Commonly (≥ 1/100 to < 1/10) reported adverse reactions included tinea infections, headache, pruritus, rash, eczema, fatigue, and injection site reactions.

This is not a complete summary of all safety information.

See Skyrizi full Summary of Product Characteristics (SmPC) at www.ema.europa.eu.

Globally, prescribing information varies; refer to the individual country product label for complete information. 

About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For more than 20 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of actions and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.

Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 19 immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References

SKYRIZI. Summary of Product Characteristics. AbbVie; 2026. Sticherling M, McPherson T, de Lucas Laguna R, et al. Patient Characteristics and Treatment Patterns in European Pediatric Patients with Psoriasis: A Real-World, Cross-Sectional Study. Dermatol Ther (Heidelb). 2022;12(8):1793-1808. doi:10.1007/s13555-022-00761-7 Yang A, Cheng B, Seyger MMB, Murphy R, Stoll ML, Cordoro KM, van de Kerkhof P, Paller AS. The burden of pediatric psoriasis: a systematic review. Am J Clin Dermatol. Published online 2025. doi:10.1007/s40257-025-00965-5 Bronckers IM, Paller AS, van Geel MJ, van de Kerkhof PC, Seyger MM. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Paediatr Drugs. 2015;17(5):373-384. doi:10.1007/s40272-015-0137-1 Seyger MMB, Augustin M, Sticherling M, et al. Physician-reported Clinical Unmet Needs, Burden and Treatment Patterns of Paediatric Psoriasis Patients: A US and EU Real-world Evidence Study. Acta Derm Venereol. 2022;102:adv00660. Published 2022 Feb 28. doi:10.2340/actadv.v101.981 SOURCE AbbVie

SKYRIZI® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis1Approval was based on the pivotal Phase 3 OptIMMize-1 and OptIMMize-2 trials which include a new 55 mg pre-filled syringe to support weight-based dosing for patients weighing less than 40 kg1Nearly a third of people living with psoriasis develop symptoms before the age of 18, often getting lesions on highly visible areas2,3, /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI® (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque psoriasis who are candidates for systemic therapy. The approval includes a new 55 mg pre-filled syringe (PFS) to support weight-based dosing for patients weighing less than 40 kg.1

"Plaque psoriasis in children carries its own clinical complexity and urgency to provide additional efficacious treatment options," said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. "Today's approval of SKYRIZI for pediatric psoriasis patients is a meaningful step forward for millions worldwide who are looking for additional treatment options to better manage this chronic disease in their formative years."

Nearly a third of people living with psoriasis develop symptoms before the age of 18, often getting lesions on highly visible areas.2,3 Because children often have facial or scalp involvement, the early-onset of psoriasis increases the risk of school absenteeism, potential social stigma, and development of other comorbidities.3,4 Despite the significant impact of the disease on children's quality of life, nearly 70% of pediatric patients rely solely on topical therapies.5

Data Supporting the EC Approval

The EC's approval of SKYRIZI in pediatric patients is supported by clinical data from the Phase 3 OptIMMize-1 pediatric psoriasis program (NCT04435600), including data from two lead-in pharmacokinetic cohorts: a randomized efficacy assessor-blinded, active-controlled cohort (12 to <18 years), and a single-arm, open-label cohort (6 to <12 years), in addition to the Phase 3 OptIMMize-2 open-label extension study (NCT04862286). The safety profile in pediatric patients (n=137) treated with SKYRIZI was consistent with that observed in adults with moderate to severe plaque psoriasis, with no new safety signals observed.1

"Particularly for pediatric psoriasis patients, early diagnosis and management can prevent symptoms from worsening and improve quality of life in the long-term," said Nina Magnolo, M.D., Department of Dermatology, University Hospital of Münster, and lead investigator of the OptIMMize-1 study. "The EC's approval of risankizumab provides younger patients with more options including weight-based dosing and allows physicians to address unmet clinical needs of children living with moderate to severe psoriasis with confidence."

About SKYRIZI® (risankizumab)
SKYRIZI is an interleukin (IL)-23 inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases. SKYRIZI is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis in adults.

EU Indications and Important Safety Information about Skyrizi® (risankizumab)1

Indications

Skyrizi (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.

Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).

Skyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Skyrizi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Important Safety Information

Risankizumab is contraindicated in patients hypersensitive to the active substance or to any of the excipients, and in patients with clinically important active infections (e.g. active tuberculosis).

Risankizumab may increase the risk of infection. In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, risankizumab should be used with caution. Treatment with risankizumab should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.

Patients treated with risankizumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops such an infection or is not responding to standard therapy for the infection, the patient should be closely monitored and risankizumab should not be administered until the infection resolves.

Prior to initiating treatment with risankizumab, patients should be evaluated for tuberculosis (TB) infection. Patients receiving risankizumab should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating risankizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.

Prior to initiating therapy with risankizumab, completion of all appropriate immunisations should be considered according to current immunisation guidelines. If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab. Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment.

Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of risankizumab. If a serious hypersensitivity reaction occurs, administration of risankizumab should be discontinued immediately and appropriate therapy initiated.

The most frequently reported adverse reactions were upper respiratory infections (13% in psoriasis, 15.6% in Crohn's disease and 26.2% in ulcerative colitis).

Commonly (≥ 1/100 to < 1/10) reported adverse reactions included tinea infections, headache, pruritus, rash, eczema, fatigue, and injection site reactions.

This is not a complete summary of all safety information.

See Skyrizi full Summary of Product Characteristics (SmPC) at www.ema.europa.eu.

Globally, prescribing information varies; refer to the individual country product label for complete information.

About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For more than 20 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of actions and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.

Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 19 immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References

SKYRIZI. Summary of Product Characteristics. AbbVie; 2026.Sticherling M, McPherson T, de Lucas Laguna R, et al. Patient Characteristics and Treatment Patterns in European Pediatric Patients with Psoriasis: A Real-World, Cross-Sectional Study. Dermatol Ther (Heidelb). 2022;12(8):1793-1808. doi:10.1007/s13555-022-00761-7Yang A, Cheng B, Seyger MMB, Murphy R, Stoll ML, Cordoro KM, van de Kerkhof P, Paller AS. The burden of pediatric psoriasis: a systematic review. Am J Clin Dermatol. Published online 2025. doi:10.1007/s40257-025-00965-5Bronckers IM, Paller AS, van Geel MJ, van de Kerkhof PC, Seyger MM. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Paediatr Drugs. 2015;17(5):373-384. doi:10.1007/s40272-015-0137-1Seyger MMB, Augustin M, Sticherling M, et al. Physician-reported Clinical Unmet Needs, Burden and Treatment Patterns of Paediatric Psoriasis Patients: A US and EU Real-world Evidence Study. Acta Derm Venereol. 2022;102:adv00660. Published 2022 Feb 28. doi:10.2340/actadv.v101.981 View original content:https://www.prnewswire.com/news-releases/abbvie-announces-european-commission-approval-of-skyrizi-risankizumab-for-the-treatment-of-pediatric-patients-with-moderate-to-severe-plaque-psoriasis-302807045.html

SOURCE AbbVie

MAVIRET® (glecaprevir/pibrentasvir) is now approved in the European Union for the treatment of acute hepatitis C virus (HCV) infection with compensated liver disease (with or without cirrhosis) in adults and children aged 3 years and older. The approval gives clinicians an option to initiate treatment as soon as acute infection is confirmed, aiming to reduce delays in care and lower the risk of liver disease progression, cirrhosis and liver cancer. As the only treatment approved in the EU for both acute and chronic HCV infection, MAVIRET may help streamline care pathways and support broader efforts to advance HCV elimination goals. , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission approved MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy for the treatment of acute hepatitis C virus (HCV) infection in adults and children aged 3 years and older. With this approval, MAVIRET is now the only treatment approved in the European Union for both acute and chronic HCV infection.

"More than 12 million people in Europe live with hepatitis C, underscoring the need for earlier treatment," said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. "Today's European Commission approval of MAVIRET for acute hepatitis C infection enables earlier intervention, aiming to help more people access curative therapy at the time of diagnosis, while accelerating progress toward the goal of eliminating hepatitis C as a public health threat."

HCV is a highly infectious blood-borne disease that often goes undetected because people may not show symptoms.1 While HCV is curable, many people remain undiagnosed.1 If left untreated, HCV can progress to severe liver complications, including cirrhosis and end-stage liver disease.1 Current clinical guidance supports treating nearly all people with acute or chronic HCV infection.2

"People living with HCV infection frequently face delayed treatment, leading to loss to care and onward transmission," said Massimo Puoti, MD, director of the Infectious Diseases Department at Niguarda Hospital in Milan, Italy. "With this approval, healthcare professionals across the European Union now have an approved treatment option to treat patients at the earliest stage of infection, supporting prompt intervention and helping to reduce transmission, disease progression, and long-term complications for people living with hepatitis C."

Globally, HCV poses a substantial health and economic burden3, with over 200,000 deaths each year from liver cancer.1 People living with HCV are up to 17 times more likely to develop liver cancer than those unaffected.4

The approval was supported by data from the Phase 3, multicenter, single-arm prospective study evaluating the safety and efficacy of MAVIRET eight-week treatment regimen in patients with acute HCV infection.5 The study results showed MAVIRET to be a highly efficacious treatment for people with acute HCV.5 The majority of the adverse events reported were mild or moderate in severity.5 The most common adverse events were fatigue, diarrhea, headache, and asthenia.5

AbbVie continues to collaborate with global regulatory authorities to support access to MAVIRET for people living with acute HCV infection. MAVIRET is approved in the United States, Saudi Arabia, New Zealand, Canada, Taiwan, Australia and Argentina for the treatment of acute and chronic HCV infection in adults and children aged 3 years and older.

About the Phase 3 M20-350 Study5
The multicenter, single-arm prospective Phase 3 M20-350 clinical trial was designed to evaluate the safety and efficacy of MAVIRET (glecaprevir/pibrentasvir) eight-week treatment in adults and adolescent participants aged 12 years and older with acute HCV infection. The study enrolled 286 treatment-naïve adult patients with acute HCV infection across 70 locations globally. Patients received oral tablets of MAVIRET once daily for eight weeks and were followed for 12 weeks after the end of treatment. The primary endpoint was the percentage of patients with sustained virological response 12 weeks post-treatment (SVR12) in the intent-to-treat population (ITT). The study met its primary endpoint, with 96.2% of patients in the ITT population achieving SVR12 (p<0.0001). The key secondary endpoint was also met with 100% of patients in the modified ITT-Virologic Failure population achieving SVR12 (p<0.0001). No on-treatment virologic failures or post-treatment relapses were observed, and post-treatment reinfection occurred in 0.7% of patients.

The overall safety profile observed in the M20-350 study was similar to that observed in patients with chronic HCV infection. No serious adverse reactions or adverse reactions leading to treatment discontinuation that were judged as treatment-related were observed among patients with acute HCV infection. The most commonly reported adverse reactions were fatigue (3%), asthenia (2%), headache (2%), and diarrhea (2%).

More information on the study can be found at www.clinicaltrials.gov (NCT04903626).

About MAVIRET® (glecaprevir/pibrentasvir)
MAVIRET® (glecaprevir/pibrentasvir) is an oral, pangenotypic, once-daily, ribavirin-free direct-acting antiviral treatment for acute and chronic hepatitis C virus (HCV) infection in adults and children 3 years and older. MAVIRET combines glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor, and is administered once daily with food. In the European Union, MAVIRET is approved for the treatment of acute and chronic HCV infection in adults and children aged 3 years and older.

Important EU Safety Information:

CONTRAINDICATIONS: 
MAVIRET is contraindicated in patients with severe hepatic impairment (Child-Pugh C). Concomitant use of MAVIRET is contraindicated with atazanavir-containing products, atorvastatin, simvastatin, dabigatran etexilate, ethinyl oestradiol-containing products, strong P-gp and CYP3A inducers (e.g., rifampicin, carbamazepine, St. John's wort [Hypericum perforatum], phenobarbital, phenytoin, and primidone).

SPECIAL WARNINGS AND PRECAUTIONS FOR USE:

Hepatitis B virus reactivation 
Cases of hepatitis B virus (HBV) reactivation, some of them fatal, have been reported during or after treatment with direct-acting antiviral agents. HBV screening should be performed in all patients before initiation of treatment. HBV/HCV co-infected patients are at risk of HBV reactivation, and should, therefore, be monitored and managed according to current clinical guidelines.

Hepatic impairment 
MAVIRET is not recommended in patients with moderate hepatic impairment (Child-Pugh B).

Patients who failed a prior regimen containing an NS5A and/or an NS3/4A inhibitor 
MAVIRET is not recommended for the re-treatment of patients with prior exposure to NS3/4A and/or NS5A inhibitors.

Use in diabetic patients 
Patients with diabetes may experience improved glucose control and potential symptomatic hypoglycaemia after initiating HCV direct-acting antiviral treatment. Glucose levels should be closely monitored, particularly within the first 3 months of treatment.

ADVERSE REACTIONS 
In pooled Phase 2 and 3 clinical studies of adult subjects receiving MAVIRET with genotype 1, 2, 3, 4, 5 or 6 chronic HCV infection the most commonly reported adverse reactions were headache and fatigue.

In a Phase 3b clinical study of adult subjects receiving MAVIRET with genotype 1, 2, 3, or 4 acute HCV infection the most commonly reported adverse reactions were fatigue, asthenia, headache and diarrhoea.

This is not a complete summary of all safety information. See MAVIRET full summary of product characteristics (SmPC) at www.ema.europa.eu.

Globally, prescribing information varies; refer to the individual country product label for complete information.

About AbbVie in Hepatitis C 
At AbbVie, our mission begins with putting patients at the center of everything we do. We engage with those affected by hepatitis C (HCV) to understand their needs and work alongside partners and healthcare professionals worldwide to advance solutions and accelerate the elimination of HCV. By raising the standard of care and focusing on closing gaps in the care cascade, we aim for a remarkable impact on patients and transformative change in communities. Every step today brings us closer to global HCV elimination. For more information, visit www.abbvie.com.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology and neuroscience – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X, and YouTube.

Forward-Looking Statements 

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

Contact(s):

Global Media:
Amber Landis
+1 (231) 557-6596
[email protected]

Investors: 
Liz Shea
[email protected]

References

1 Hepatitis C. World Health Organization. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c.
2 European Association for the Study of the Liver, et al. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020 Nov;73(5):1170-1218.
3 Cacoub P. Comment on Nuño Solinís R, et al. "Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence". Infect Dis Ther. 2017 Jun;6(2):297-301.
4 De Oliveria Andrade LJ., et al. Association between hepatitis C and hepatocellular carcinoma. J Glob Infect Dis. 2009 Jan;1(1):33-7.
5 MAVIRET® Summary of Product Characteristics. AbbVie; 2026. 

SOURCE AbbVie

© gorodenkoff / iStock via Getty Images

Big pharma’s appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a question every healthcare portfolio manager is asking: who will be next? The Apogee setup is the template buyers are chasing: late-stage clinical data, a meaningful addressable market, a strategic fit in immunology, obesity, or oncology, and a market cap that leaves room for a premium.

Using that framework, three Nasdaq-listed names keep surfacing on Wall Street’s M&A watchlists. None has announced a deal. All three carry catalysts inside the next 12 months that could either invite a bid or remove the discount. Here is the countdown, from least likely to most likely to be acquired.

3. Nektar Therapeutics Nektar Therapeutics (NASDAQ: NKTR) carries the strongest immunology storyline of the group, but the setup is the least urgent. Rezpegaldesleukin, a first-in-class Treg stimulator, hit its primary endpoint in moderate-to-severe atopic dermatitis and is heading into Phase 3 ZENITH-AD initiation by July 2026, with an FDA End-of-Phase 2 meeting for alopecia areata also lined up. That is exactly the Apogee-style profile AbbVie just paid for.

The problem for a would-be acquirer is the entry price. Nektar is up 672.0% over the past year and 55.4% year to date, with a market cap near $2.22 billion. Management raised roughly $460 million in February and another $351 million in April, leaving over $1 billion in cash. Q1 EPS came in at −$1.82, missing the −$1.48 consensus by 22.97%, with revenue of $10.86 million. Freshly funded and pre-Phase 3, Nektar has the resources to remain independent.

2. Viking Therapeutics Viking Therapeutics (NASDAQ: VKTX) is the most-rumored M&A name in biotech. VK2735 is a GLP-1/GIP dual agonist in both subcutaneous and oral formulations, sitting in the hottest therapeutic category for big pharma. The oral asset showed up to 12.2% mean body weight reduction after 13 weeks in Phase 2, and Phase 3 VANQUISH-1 is fully enrolled with over 4,500 patients ahead of schedule.

So why didn’t it top this list? Because of its size and cash. Viking carries a market cap near $3.76 billion, the largest of the trio, and held approximately $706 million in cash at year-end 2025. Polymarket traders are pricing a 36% probability of an acquisition before 2027, the second-highest odds on the platform’s M&A board. Q4 EPS missed at −$1.38 versus −$0.90, but the market has shrugged off losses. High appeal, lower urgency. Viking can command a steep premium on its own timeline.

1. Syndax Pharmaceuticals Syndax Pharmaceuticals (NASDAQ: SNDX) has the cleanest takeover setup: the smallest market cap of the three at roughly $1.71 billion, commercial-stage with two FDA-approved drugs, and a built-in strategic acquirer already on the cap table.

Revuforj, a menin inhibitor for relapsed/refractory AML, generated $48.92 million in Q1 2026 net revenue, up 144% year over year. Niktimvo, the CSF-1R antibody for chronic GVHD, is co-commercialized with Incyte and captured ~32% share of the 3L+ chronic GVHD market within its first year. Total Q1 revenue hit $64.86 million, up 223.6% year over year, with EPS of −$0.48 beating the −$0.59 estimate by 18.75%.

Shares are down 8.0% year to date and trade well below their $39 analyst target price, against a 52-week range of $8.59 to $25.59. Analyst coverage skews positive. Cash sits at $352 million, down from $394 million a quarter earlier, and 2026 opex is guided to roughly $400 million. That burn against a depressed share price makes a strategic acquirer the cheapest path forward, and Incyte’s existing Niktimvo partnership economics make it the most logical buyer.

The Bottom Line The Apogee deal proved that big pharma will pay up for late-stage immunology, and that read-through extends to obesity and oncology assets that match the criteria. Nektar has the science but not the urgency. Viking has the asset everyone wants but the leverage to wait. Syndax has the smallest cap, two launched drugs, real revenue traction, and a partner who already knows the franchise. If the Apogee playbook repeats, Syndax is the one to watch first.

Drilling commenced on the ridge at the Stibium antimony-gold prospect.

Nova Minerals Corp (ASX:NVA, NYSE-A:NVA, FRA:QM30) has completed its redomicile to the United States and started key 2026 field work at its Estelle Gold and Critical Minerals Project in Alaska, including drilling for antimony and gold.

The company’s common stock and listed warrants were now trading on the NYSE American under the ticker symbols NVA and NVAWS, while Chess Depositary Interests continue to trade on the ASX under NVA.

Drilling underway at Stibium and RPM Drilling at the Stibium antimony-gold prospect started in early June from an existing ridge-top drill pad, targeting stibnite-bearing veins identified at surface.

Gold drilling also began on June 17, from a new pad at the northern end of the main RPM ridge, with work targeting gold geochemical anomalies.

Nova said the 2026 RPM program would continue testing new zones along the two-mile-long ridge while further advancing resource definition at the RPM North and RPM Valley deposits.

Drill on RPM ridge line.

ZTEM survey completed across claim block A nearly 2,000 line-mile Z-Axis Tipper Electromagnetic airborne geophysical survey has been completed across the company’s entire claim block.

The survey has identified numerous reduced intrusion-related gold systems across the region, with data processing and interpretation pending. Nova expects the results to improve exploration targeting, particularly at RPM and West Wing.

Field crews are also progressing prospect mapping, sampling and generative exploration as seasonal conditions improve. The 2026 exploration effort is focused on the greater RPM area, West Wing and Portage Pass.

Access and infrastructure works advance Nova said about six miles of trail had been established from the airstrip toward Stibium, with construction continuing.

Camp improvement work is also underway, alongside material site preparation, airstrip expansion and engineering and design plans for construction of antimony processing and refining facilities.

Chief executive Christopher Gerteisen said the 2026 field season was ramping up, “with up to four drill rigs focused on expanding our gold and antimony resources”.

He said the company continued to execute on its US Department of Defense-funded antimony project, supported by US$43.4 million in funding, and that procurement of key mining and processing equipment was complete.

Crusher screener plant assembly in process at Whiskey Bravo site.

Amara Minerals investment lifted Nova has also increased its investment in Amara Minerals by participating in a A$500,000 share placement at A$0.005 per share and receiving listed options on a 1-for-2 basis, exercisable at A$0.008 and expiring on May 1, 2029.

The investment gives Nova exposure to Amara’s gold-antimony projects in an Australian district near Fosterville and Costerfield, with Nova retaining a right of first refusal over antimony offtake.

What's ahead Nova said antimony ore extraction and process plant construction remained on schedule to begin this year, while the broader Estelle work program would continue to target new discoveries and advance more than 20 existing prospects across a project area spanning more than 200 square miles.

The company describes Estelle as hosting 2 defined multi-million-ounce gold resources along a 35-kilometre mineralised trend in Alaska’s Tintina Gold Belt.

The deal comes as the largest after AbbVie acquired Botox maker Allergan for a massive $63 billion.

Zumilokibart Fits AbbVie’s Immunology StrategyWilliam Blair on Monday wrote, "While we do consider the nearly $11 billion price tag for an asset that will not be accretive until 2032 to be fairly expensive, the lead asset zumilokibart clearly fits within a therapeutic area where AbbVie has had commercial success for over a decade and offers the potential to further expand the company’s I&I pipeline into respiratory indications."

Analyst Matt Phipps further added that the timing of the acquisition allows AbbVie to meaningfully expand and accelerate the Phase 3

development of zumilokibart and reduce future potential royalties to Blackstone Life Sciences, and therefore, the move justifies the near-term dilution.

Zumilokibart Data Highlights Potential Blockbuster OpportunityAbbVie highlighted that the EASI100 rate achieved with zumilokibart was high (16.5% with zumilokibart versus 3.4% with placebo), nearly approaching Rinvoq-like efficacy (EASI100 rate of 14.8% at week 16).

The mega-blockbuster potential of zumilokibart ensures the company’s I&I franchise continues to see robust growth throughout the 2030s, with longer-term upside coming from fixed-dose combinations, including with the TSLP antibody APG33.

The deal highlights investors’ confidence in the long-term outlook for the company, and hence, William Blair reiterated an Outperform rating.

In January, Apogee shared interim data from the Phase 1b trial of zumilokibart in patients with mild-to-moderate asthma.

Robust and durable suppression of FeNO, a biomarker of Type 2 inflammation that has shown the strongest correlation with exacerbations in asthma, following a single dose.

ABBV Price Action: AbbVie shares were up 2.12% at $234.88 at the time of publication on Tuesday, according to Benzinga Pro data.

Photo: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

250 Women Entrepreneurs Have Been Selected to Join a Multi-Week Skill-Building, Mentorship, and Networking Program BOTOX® Cosmetic Will Award 20 Participants With $20,000 Grants Each to Help Take Their Business Dreams to the Next Level , /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the 2026 cohort of entrepreneurs selected to participate in The Confidence Collective: Empowering Women Entrepreneurs, an ongoing initiative from BOTOX® Cosmetic dedicated to uplifting and investing in women businessowners.

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective’s Entrepreneur Class of 2026. Learn more at https://botoxcosmetic.com/real-impact. This year's cohort was selected from a highly competitive and talented applicant pool spanning diverse industries, backgrounds, and business concepts, underscoring strong demand for programs that support women entrepreneurs. BOTOX® Cosmetic continues to invest where it matters most by providing participants with skill-building resources, meaningful mentorship opportunities, and for 20 entrepreneurs, access to business-affirming capital.

"Through The Confidence Collective, BOTOX® Cosmetic is proud to support women entrepreneurs with the tools and resources they need to grow," said Nicole Mowad-Nassar, senior vice president, AbbVie and president, global Allergan Aesthetics. "Each of these founders brings a unique vision and voice. This program is designed to help build confidence, foster community, and propel their businesses forward. We are excited to spotlight their stories and champion their journeys in the months ahead."

Participants kicked off the program at a virtual community summit earlier this month, focused on business development, financial education, and connection. Building on this momentum, the program continues with an intensive "Boost Camp," a multiweek experience featuring practical tools and mentorship across specialized tracks, designed to support each entrepreneur's business goals.

From the 250 women businessowners, 20 program participants will be selected by a panel of Allergan Aesthetics executives and aesthetic provider entrepreneurs to each receive a $20,000 grant from BOTOX® Cosmetic to help make their business goals a reality. This year's aesthetic entrepreneur advisors and judges include:

Jennifer Cobbs, board-certified physician associate at SkinLab Atlanta Lisa Espinoza, MD, board-certified physician, and founder of La Chelé Medical Aesthetics and Wellness Lycia Thornburg, MD, FAAD, board-certified dermatologist and founder of Lycia Thornburg, M.D. Dermatology Neekan Rivera, board-certified physician associate, founder of Aère Aesthetics Shawna Chrisman, board-certified nurse practitioner, founder of Destination Aesthetics Medical Spa™, chief aesthetics officer at Advanced MedAesthetic Partners "Having been involved from the beginning, I've seen firsthand how The Confidence Collective helps women step more fully into their role as leaders," said Chrisman, four-time aesthetic entrepreneur advisor and judge. "Being surrounded by a community where entrepreneurs support and believe in each other, I can't help but feel inspired and motivated by their stories as I continue my own entrepreneurial journey." 

The 20 grant recipients will be announced this fall. For more information on The Confidence Collective, visit www.botoxcosmetic.com/real-impact and follow @botoxcosmetic on Instagram and YouTube, where participants will be featured in the coming months.

About Allergan Aesthetics 
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com. 

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Approved Uses
BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, frown lines between the eyebrows, and vertical bands connecting the jaw and neck (platysma bands) in adults.

IMPORTANT SAFETY INFORMATION

BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:

Problems swallowing, speaking, or breathing, due to weakening of associated muscles, which can be severe and result in loss of life. You are at the highest risk if these problems are preexisting before injection. Swallowing problems may last for several months. Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms, including loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing. BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.

There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, forehead lines, and/or platysma bands.

BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of receiving BOTOX® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities.

Serious and/or immediate allergic reactions have been reported, including itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint.

Do not receive BOTOX® Cosmetic if you are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc (rimabotulinumtoxinB), Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Jeuveau (prabotulinumtoxinA-xvfs), Daxxify (daxibotulinumtoxinA-lanm), or Letybo (letibotulinumtoxinA-wlbg); or have a skin infection at the planned injection site. This list may not include all available botulinum toxin products.

Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects, including difficulty swallowing and difficulty breathing, from standard doses of BOTOX® Cosmetic.

Tell your doctor about all your medical conditions, including surgery or plans to have surgery on your face, trouble raising your eyebrows, drooping eyelids, any other abnormal facial change, are pregnant or plan to become pregnant (it is not known if BOTOX® Cosmetic can harm your unborn baby), or are breastfeeding or plan to (it is not known if BOTOX® Cosmetic passes into breast milk).

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX® Cosmetic in the past.

Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc, Dysport, Xeomin, Jeuveau, Daxxify, or Letybo in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; or take aspirin-like products or blood thinners.

Other side effects of BOTOX® Cosmetic include dry mouth; discomfort or pain at the injection site; tiredness; headache; neck pain; and eye problems, including double vision, blurred vision, decreased eyesight, drooping eyelids and eyebrows, swelling of eyelids, and dry eyes.

For more information, refer to the Medication Guide or talk with your doctor. To report a side effect, please call Allergan Aesthetics at 1-800-678-1605.

See BOTOX® Cosmetic full Product Information, including Boxed Warning and Medication Guide.

© 2026 AbbVie. All rights reserved. BOTOX Cosmetic and its designs are trademarks of Allergan Holdings France SAS, an AbbVie company, or its affiliates. 

Contacts:

Investors:
Liz Shea
[email protected]
(847) 935-2211 

Media:
Ember Garrett
[email protected]
(714) 246-3525 

SOURCE AbbVie

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +24% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: SSR Mining (SSRM - Free Report) SSR Mining Inc. is a precious metals miner engaged in the operation, acquisition, exploration and development of gold and silver assets across four key jurisdictions: the United States, Türkiye, Canada and Argentina. Incorporated in British Columbia in 2005, the company is headquartered in Denver, Colorado. Its portfolio is anchored in several of the world’s most prolific mineral belts. These include the Çöpler mine along the Tethyan Metallogenic Belt in Türkiye; the Marigold mine situated on Nevada’s Battle Mountain–Eureka trend; the Cripple Creek & Victor (CC&V) mine in Colorado’s historic Cripple Creek Mining District; the Seabee operation along the Trans-Hudson Corridor in Saskatchewan, Canada; and the Puna operation positioned within the Bolivian silver belt in Jujuy, Argentina.

SSRM is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Momentum investors should take note of this Basic Materials stock. SSRM has a Momentum Style Score of A, and shares are up 7.5% over the past four weeks.

Two analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.79 to $4.50 per share. SSRM also boasts an average earnings surprise of +54%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, SSRM should be on investors' short list.

DENVER--(BUSINESS WIRE)--SSR Mining Inc. (Nasdaq/TSX: SSRM) ("SSR Mining" or the “Company") is pleased to announce that it has published its 2025 Sustainability Report (“Report”), which outlines the Company’s 2025 performance as well as its approach to sustainability across a range of areas, including Health & Safety, environment, communities, and diversity.

2025 Sustainability Performance Highlights

Re-used or recycled approximately 92% of water used across the Company’s operating mine sites, led by strong performance from our Marigold and Cripple Creek & Victor operations in the USA. Invested over $1.6 million in strategic community-specific initiatives, a more than 55% increase over 2024. During the year, our Community Development Committees became fully operational, with greater emphasis on funding longer-term, sustainable initiatives across our portfolio. Advanced an improved safety management system, prioritizing the development of a stronger proactive reporting culture and recognizing reporting on potential significant incidents (pSIs). Our “I Care, We Care” philosophy, to be rolled out globally in 2026, reinforces our commitment to eliminating fatalities, reducing injuries and removing high-impact risks from our operations. No workplace fatalities or life-altering injuries were reported in 2025. The Report presents an overview of the sustainability performance during the year from January 1, 2025 to December 31, 2025 across SSR Mining’s corporate office and four operating mines. While adapting reporting practices to better align with immediate operational and stakeholder needs, SSR Mining continues to prepare the Report with reference to the Global Reporting Initiative (GRI) and Sustainability Accounting Standards Board (SASB) standards referenced in prior reports. The material topics presented in the Report were informed by a structured materiality pre-assessment undertaken in preparation for SSR Mining’s comprehensive double materiality assessment planned for 2026. The Report can be accessed on SSR Mining’s website at: www.ssrmining.com/corporate_responsibility

About SSR Mining

SSR Mining is listed under the ticker symbol SSRM on the Nasdaq and the TSX.

For more information, please visit: www.ssrmining.com.

Cautionary Note Regarding Forward-Looking Information and Statements:

This press release includes “forward looking information” within the meaning of applicable securities laws. Forward-looking information can be identified by terminology such as “may”, “will”, “could”, “should”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “estimate”, “projects”, “predict”, “potential”, “continue” or other similar expressions concerning matters that are not historical facts. Statements that refer to projections of our future financial performance, our anticipated growth and trends in our businesses, and other characterizations of future events or circumstances are forward-looking statements, and include, but are not limited to, local and global political and economic conditions; governmental and regulatory requirements and actions by governmental authorities, including changes in government policy, government ownership requirements, changes in environmental, tax and other laws or regulations and the interpretation thereof; developments with respect to global pandemics, including the duration, severity and scope of a pandemic and potential impacts on mining operations; and any and all other timing, exploration, development, operational, financial, budgetary, economic, legal, social, environmental, regulatory, and political matters that may influence or be influenced by future events or conditions.

Although we believe that the expectations and assumptions on which such forward-looking information and statements are based are reasonable, you should not place undue reliance on the forward-looking information and statements because we can give no assurance that they will prove to be correct. Forward-looking information and statements are subject to various risks and uncertainties which could cause actual results and expectations to differ materially from the anticipated results or expectations expressed in this press release. Important factors that could cause actual results to differ materially from our historical experience, and present projections and expectations are disclosed in our filings that we make on SEDAR+ at www.sedarplus.ca, and on EDGAR at www.sec.gov, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions. Forward-looking information and statements speak only as of the date they are made. Other than as required by law, we do not intend, and undertake no obligation to update any forward-looking information and statements to reflect, among other things, new information or events. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.

More News From SSR Mining Inc.

DETROIT, MI / ACCESS Newswire / June 22, 2026 / Leggett Dynamics today launched its Mid-Class Massage System (MCM), a breakthrough non-electronic innovation that makes premium massage more accessible beyond the luxury vehicle segment. Now in production with a global OEM, MCM was also shortlisted for the 2026 Auto Tech Partnership Award for industry-leading innovation and collaboration.

Breakthrough by Design

MCM creates a distinctive massage experience with a compact 30 x 35 mm module that uses the Coandă effect, an air jet's natural tendency to follow a curved surface. With no electronics or moving parts, it reduces complexity and cost, making a premium experience accessible to more vehicle segments and consumers.

Balancing Innovation, Speed and Cost

"Automakers must balance innovation, speed and cost while consumers expect more personalized, affordable, premium experiences," said Julien Rea, VP of Global Innovation & Engineering at Leggett Dynamics. "Leggett Dynamics' Mid-Class Massage System redefines what's possible with a breakthrough approach that simplifies design, enables plug-and-play integration and makes premium comfort accessible to more vehicles beyond the luxury segment."

As part of its Innovation Services, Leggett Dynamics generated early OEM interest with an advanced concept and launched a co-development program to validate technical feasibility, optimize performance, and align cost targets with market expectations.

Accelerating Concept to Production

MCM's rapid transition from concept to production was enabled by early collaboration and its stand-alone, non-electronic design. Unlike conventional systems, MCM can be integrated as an "island solution" in vehicle updates without requiring time-consuming and costly electronic revalidation. This helps OEMs quickly and easily add comfort content, even on platforms not originally designed with complex electronic architectures.

Recognition for Innovation and Partnership

MCM was shortlisted for the 2026 Automotive Tech Partnership Award, reflecting recognition for both breakthrough innovation and the power of close OEM collaboration. MCM is also under consideration for additional industry awards to be announced later this year.

"Helping automakers balance cutting-edge innovation, speed, and cost is exactly why early co-development matters. When collaboration starts early, we can better align advanced concepts with cost targets and launch timing to bring differentiated user experiences to market faster and help OEMs compete more effectively," said Rea.

Leggett Dynamics showcased MCM last week at the Automotive Engineering Expo in Nagoya, Japan) and will feature this and other innovations at the Automotive Interiors Expo Europe in Stuttgart, Germany (June 23-25, Booth #3216).

About Leggett Dynamics
Leggett Dynamics is the brand representing the automotive businesses of Leggett & Platt, Incorporated. Under the Leggett Dynamics brand, these businesses deliver eMotion and Comfort solutions for automotive seating, liftgates, doors, sunroofs, and more. Leggett Dynamics businesses operate globally, with a footprint spanning 28 locations across 12 countries, and employing more than 6,200 people, with key locations in Detroit, Nuremberg, and Shanghai. As a strategic partner to more than 140 customers worldwide, Leggett Dynamics offers a Comfort Systems Platform (massage, lumbar, bolster and suspension), Motion Systems Platform (motors, actuators and cables), Software & Integration Platform, and Innovation Services, including advanced engineering co-development and human factors studies. Leggett Dynamics is a brand within Leggett & Platt, Inc. (NYSE:LEG), a manufacturer of residential, industrial, and furniture products that has been engineering comfort for over 140 years across the places where people sleep, work, live, and move.

Link to Press Kit: MCM Launch

Media Contact:

Dawn K. Looney, APR
VP of Global Branding, Marketing & Communications
Leggett Dynamics
Email: [email protected]
Phone: +1.248.980.1248

Liwen Tao
Manager of AP Branding, Marketing & Communications
Leggett Dynamics
Email: [email protected]

SOURCE: Leggett & Platt